

RECEIVED
CENTRAL FAX CENTER

NOV 07 2006

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being transmitted by facsimile to the Patent and Trademark Office, facsimile no. (571) 273-8300, on the date shown below.

Dated: November 7, 2006

Signature: *Sandy Yi*

(Sandy Yi)

Patent

Docket No. 282172002900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:

Thomas W. DUBENSKY, Jr. et al.

Examiner:

J. Graser

Serial No.: 10/773,792

Group Art Unit:

1645

Filing Date: February 6, 2004

For: LISTERIA ATTENUATED FOR ENTRY
INTO NON-PHAGOCYtic CELLS,
VACCINES COMPRISING THE
LISTERIA, AND METHODS OF USE
THEREOF

SUPPLEMENTAL INFORMATION DISCLOSURE
STATEMENT UNDER 37 C.F.R. § 1.97 & 1.98

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Dear Sir:

Pursuant to 37 C.F.R. §1.97 and § 1.98, Applicants submit for consideration in the above-identified application the documents listed on the attached Form PTO/SB/08a/b. The Examiner is requested to make these documents of record.

This Supplemental Information Disclosure Statement is submitted:

- ☐ With the application; accordingly, no fee or separate requirements are required.
- ☐ Before the mailing of a first Office Action after the filing of a Request for Continued Examination under § 1.114. However, if applicable, a certification under 37 C.F.R. § 1.97 (e)(1) has been provided.

Application Serial No. 10/773,792

Patent

Docket No. 282172002900

- ☒ Within three months of the application filing date or before mailing of a first Office Action on the merits; accordingly, no fee or separate requirements are required. However, if applicable, a certification under 37 C.F.R. § 1.97 (e)(1) has been provided.
- ☐ After receipt of a first Office Action on the merits but before mailing of a final Office Action or Notice of Allowance.
- ☐ A fee is required. A check in the amount of ___ is enclosed.
- ☐ A fee is required. Accordingly, a Fee Transmittal form (PTO/SB/17) is attached to this submission in duplicate.
- ☐ A Certification under 37 C.F.R. § 1.97(e) is provided above; accordingly, no fee is believed to be due.
- ☐ After mailing of a final Office Action or Notice of Allowance, but before payment of the issue fee.
- ☐ A Certification under 37 C.F.R. § 1.97(e) is provided above and a check in the amount of ___ is enclosed.
- ☐ A Certification under 37 C.F.R. § 1.97(e) is provided above and a Fee Transmittal form (PTO/SB/17) is attached to this submission in duplicate.

Applicants would appreciate the Examiner initialing and returning the Form PTO/SB/08a/b, indicating that the information has been considered and made of record herein.

The information contained in this Supplemental Information Disclosure Statement under 37 C.F.R. § 1.97 and § 1.98 is not to be construed as a representation that: (i) a complete search has been made; (ii) additional information material to the examination of this application does not exist; (iii) the information, protocols, results and the like reported by third parties are accurate or enabling; or (iv) the above information constitutes prior art to the subject invention.

In the unlikely event that the transmittal form is separated from this document and the Patent and Trademark Office determines that an extension and/or other relief (such as payment of a fee under 37 C.F.R. § 1.17 (p)) is required, Applicants petition for any required relief including extensions of time and authorize the Commissioner to charge the cost of such petition and/or other

Application Serial No. 10/773,792

Patent
Docket No. 282172002900

fees due in connection with the filing of this document to Deposit Account No. 03-1952
referencing 282172002900.

Dated: November 7, 2006

Respectfully submitted,

By



Alicia J. Hager
Registration No.: 44,140

MORRISON & FOERSTER LLP
755 Page Mill Road
Palo Alto, California 94304-1018
(650) 813-4296


pa-1108479

3

NOV 07 2006

ALTERNATIVE TO PTO/SB08a/b (07-05)

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Complete If Known			
		Application Number	10/773,792		
		Filing Date	February 6, 2004		
		First Named Inventor	Thomas W. DUBENSKY, Jr.		
		Art Unit	1645		
		Examiner Name	J. Graser		
Sheet	1	of	1	Attorney Docket Number	282172002900

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)	MM-DD-YYYY		
	1.	US-4,545,987	10-08-1985	Giles et al.	
	2.	US-4,556,556	12-03-1985	Wiesehahn et al.	
	3.	US-4,791,062	12-13-1988	Wiesehahn et al.	
	4.	US-5,106,619-A	04-21-1992	Wiesehahn et al.	



FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ³
		Country Code ⁴ -Number ⁵ -Kind Code ⁶ (if known)	MM-DD-YYYY			

*EXAMINER: Initial if information considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 601.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.


NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ³

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.


¹Applicant's unique citation designation number (optional). ³Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	
-----------------------	---	--------------------	---

pa-1108480



I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the U.S. Postal Service as Express Mail, Airbill No. EV 586703523 US, on the date shown below in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Dated: November 2, 2006 Signature: 

(Lori Sims)

Patent

Docket No. 282172002900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Thomas W. DUBENSKY, Jr. et al.

Examiner: J. Graser

Group Art Unit: 1645

Serial No.: 10/773,792

Filing Date: February 6, 2004

For: LISTERIA ATTENUATED FOR ENTRY
INTO NON-PHAGOCYtic CELLS,
VACCINES COMPRISING THE
LISTERIA, AND METHODS OF USE
THEREOF

**SUPPLEMENTAL INFORMATION DISCLOSURE
STATEMENT UNDER 37 C.F.R. § 1.97 & 1.98**

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Dear Sir:

Pursuant to 37 C.F.R. §1.97 and § 1.98, Applicants submit for consideration in the above-identified application the documents listed on the attached Form PTO/SB/08a/b. Copies of a foreign document and non-patent literature are submitted herewith. The Examiner is requested to make these documents of record.

This Supplemental Information Disclosure Statement is submitted:

- ☐ With the application; accordingly, no fee or separate requirements are required.
- ☐ Before the mailing of a first Office Action after the filing of a Request for Continued Examination under § 1.114. However, if applicable, a certification under 37 C.F.R. § 1.97(e)(1) has been provided.

- ☒ Within three months of the application filing date or before mailing of a first Office Action on the merits; accordingly, no fee or separate requirements are required. However, if applicable, a certification under 37 C.F.R. § 1.97 (e)(1) has been provided.
- ☐ After receipt of a first Office Action on the merits but before mailing of a final Office Action or Notice of Allowance.
- ☐ A fee is required. A check in the amount of __ is enclosed.
- ☐ A fee is required. Accordingly, a Fee Transmittal form (PTO/SB/17) is attached to this submission in duplicate.
- ☐ A Certification under 37 C.F.R. § 1.97(e) is provided above; accordingly; no fee is believed to be due.
- ☐ After mailing of a final Office Action or Notice of Allowance, but before payment of the issue fee.
- ☐ A Certification under 37 C.F.R. § 1.97(e) is provided above and a check in the amount of __ is enclosed.
- ☐ A Certification under 37 C.F.R. § 1.97(e) is provided above and a Fee Transmittal form (PTO/SB/17) is attached to this submission in duplicate.

Applicants would appreciate the Examiner initialing and returning the Form PTO/SB/08a/b, indicating that the information has been considered and made of record herein.

The information contained in this Supplemental Information Disclosure Statement under 37 C.F.R. § 1.97 and § 1.98 is not to be construed as a representation that: (i) a complete search has been made; (ii) additional information material to the examination of this application does not exist; (iii) the information, protocols, results and the like reported by third parties are accurate or enabling; or (iv) the above information constitutes prior art to the subject invention.

In the unlikely event that the transmittal form is separated from this document and the Patent and Trademark Office determines that an extension and/or other relief (such as payment of a fee under 37 C.F.R. § 1.17 (p)) is required, Applicants petition for any required relief including extensions of time and authorize the Commissioner to charge the cost of such petition and/or other

Application Serial No. 10/773,792

Patent
Docket No. 282172002900

fees due in connection with the filing of this document to Deposit Account No. 03-1952
referencing 282172002900.

Dated: November 2, 2006

Respectfully submitted,

By


Alicia J. Hager

Registration No.: 44,140

MORRISON & FOERSTER LLP
755 Page Mill Road
Palo Alto, California 94304-1018
(650) 813-4296



ALTERNATIVE TO PTO/SB/08ab (07-05)

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/773,792
				Filing Date	February 6, 2004
				First Named Inventor	Thomas W. DUBENSKY, Jr.
				Art Unit	1645
				Examiner Name	J. Graser
				Attorney Docket Number	282172002900
Sheet	1	of	1		

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
	1.	WO-2005/067460-A2, A3	07-28-2005	MedImmune, Inc.		

*EXAMINER: Initial if information considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	2.	Brockstedt, D. et al. (March 2004). "The Living Dead: Psoralen-killed Metabolically Active <i>Listeria</i> DNA Repair Mutant-based Vaccines Induce Therapeutic Anti-tumor Efficacy Targeted Against an Endogenous Antigen," abstract presented at the American Association for Cancer Research (AACR), March 27-31, 2004, as posted on < http://www.cerus.com/pages/solution/abs156.html >, last visited on August 26, 2004, two pages.	
	3.	Brockstedt, D. et al. (July 2004). "The Living Dead: Psoralen-killed Metabolically Active <i>Listeria</i> DNA Repair Mutant-based Vaccines Induce Therapeutic Anti-tumor Efficacy Targeted Against an Endogenous Antigen," abstract presented at the Gordon Research Conference on Microbial Toxins and Pathogenicity, July 18 - 23, 2004, Andover, NH, as posted on < http://www.cerus.com/pages/solution/04_GordonResearchConf_Brockstedt.html >, last visited on August 26, 2004, two pages.	
	4.	Giedlin, M. et al. (March 2004). "The Living Dead: Vaccines Against Microbial Pathogens Based on Psoralen-Killed Metabolically Active DNA Repair Mutants," abstract presented at the American Society for Microbiology (ASM) Biodefense Research Meeting, March 7-10, 2004, as posted on < http://www.cerus.com/pages/solution/abs158.html >, last visited July 18, 2004, two pages.	
	5.	Moody, G. et al. (March 2004). "Recombinant <i>Listeria monocytogenes</i> -Based Immunotherapy Targeting the Receptor Tyrosine Kinase EphA2," abstract presented at the American Association for Cancer Research (AACR), March 27-31, 2004, as posted on < http://www.cerus.com/pages/solution/abs155.html >, last visited on August 26, 2004, two pages.	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

pa-1106940


I hereby certify that this correspondence is being deposited with the U.S. Postal Service as Express Mail, Airbill No. EV336621781US, in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

Dated: February 9, 2005

Signature:

Georgina Matos
(Georgina Matos)

PATENT
Docket No. 282172002900



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Thomas W. DUBENSKY, Jr. et al.

Serial No.: 10/773,792

Filing Date: February 6, 2004

For: LISTERIA ATTENUATED FOR ENTRY
INTO NON-PHAGOCYtic CELLS,
VACCINES COMPRISING THE
LISTERIA, AND METHODS OF USE
THEREOF

Examiner: J. Graser

Group Art Unit: 1645

**SUPPLEMENTAL INFORMATION DISCLOSURE
STATEMENT UNDER 37 C.F.R. § 1.97 & 1.98**

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Dear Sir:

Pursuant to 37 C.F.R. §1.97 and § 1.98, Applicants submit for consideration in the above-identified application the documents listed on the attached Form PTO/SB/08a/b. Copies of foreign documents and non-patent literature are submitted herewith. The Examiner is requested to make these documents of record.

This Supplemental Information Disclosure Statement is submitted:

- ☐ With the application; accordingly, no fee or separate requirements are required.
- ☐ Before the mailing of a first Office Action after the filing of a Request for Continued Examination under § 1.114. However, if applicable, a certification under 37 C.F.R. § 1.97 (e)(1) has been provided.
- ☒ Within three months of the application filing date or before mailing of a first Office Action on the merits; accordingly, no fee or separate requirements are required. However, if applicable, a certification under 37 C.F.R. § 1.97 (e)(1) has been provided.
- ☐ After receipt of a first Office Action on the merits but before mailing of a final Office Action or Notice of Allowance.
 - ☐ A fee is required. A check in the amount of ___ is enclosed.
 - ☐ A fee is required. Accordingly, a Fee Transmittal form (PTO/SB/17) is attached to this submission in duplicate.
 - ☐ A Certification under 37 C.F.R. § 1.97(e) is provided above; accordingly, no fee is believed to be due.
- ☐ After mailing of a final Office Action or Notice of Allowance, but before payment of the issue fee.
 - ☐ A Certification under 37 C.F.R. § 1.97(e) is provided above and a check in the amount of ___ is enclosed.
 - ☐ A Certification under 37 C.F.R. § 1.97(e) is provided above and a Fee Transmittal form (PTO/SB/17 is attached to this submission in duplicate.)

Applicants would appreciate the Examiner initialing and returning the Form PTO/SB/08a/b, indicating that the information has been considered and made of record herein.

The information contained in this Supplemental Information Disclosure Statement under 37 C.F.R. § 1.97 and § 1.98 is not to be construed as a representation that: (i) a complete search has been made; (ii) additional information material to the examination of this application does not exist;

Application Serial No. 10/773,792


PATENT
Docket No: 282172002900

(iii) the information, protocols, results and the like reported by third parties are accurate or enabling;
or (iv) the above information constitutes prior art to the subject invention.


In the unlikely event that the transmittal form is separated from this document and the Patent Office determines that an extension and/or other relief (such as payment of a fee under 37 C.F.R. § 1.17 (p)) is required, Applicants petition for any required relief including extensions of time and authorize the Commissioner to charge the cost of such petitions and/or other fees due in connection with the filing of this document to Deposit Account No. 03-1952 referencing 282172002900. However, the Commissioner is not authorized to charge the cost of the issue fee to the Deposit Account.

Dated: February 9, 2005

Respectfully submitted,

By 
Alicia J. Hager
Registration No.: 44,140


MORRISON & FOERSTER LLP
755 Page Mill Road
Palo Alto, California 94304
(650) 813-4296



ALTERNATIVE TO PTO/SB/08a/b (06-03)

Information for form 1449/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Application Number	10/773,792
				Filing Date	February 6, 2004
				First Named Inventor	Thomas W. DUBENSKY, Jr.
				Art Unit	1645
				Examiner Name	J. Graser
Sheet	1	of	2	Attorney Docket Number	282172002900

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code* (if known)			
J	1.	US-2002/0136738-A1	09-26-2002	Agrewala et al.	
	2.	US-2003/0077263-A1	04-24-2003	Maraskovsky et al.	
	3.	US-2004/0009194-A1	01-15-2004	Andrieu et al.	
	4.	US-6,150,424-A	11-21-2000	Breitenbach et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ²
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				
	5.	WO-97/22349-A1	06-26-1997	The Board of Trustees of The Leland Stanford Junior University		
	6.	WO-98/09616	03-12-1998	BASF AG <i>Abstract Only</i>	Translation of Abstract Only	
	7.	WO-01/77358-A2, A3	10-18-2001	Biovex Limited		
	8.	WO-02/40046	05-23-2002	AKZO N.V.		
	9.	WO-02/083879-A2, A3	10-24-2002	Alimentary Health Limited		

*EXAMINER: Initial if information considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T ²
J	10.	Anonymous (February 4, 2003). "Cerus Corporation Starts Vaccine Trial for Epstein-Barr Virus," <i>Press Release, Cerus Corporation</i> , located at < http://www.cerus.com/pages/PR/2003/PRO20403.html > last visited on November 8, 2004, two pages.		
	11.	Henderson, R.A. et al. (July 15, 1997). "Activation of Human Dendritic Cells Following Infection with <i>Mycobacterium tuberculosis</i> ," <i>The Journal of Immunology</i> 159(2):635-643.		
	12.	Invitation To Pay Additional Fees mailed January 5, 2005, for PCT Application Number PCT/US2004/023881 filed July 23, 2004, seven pages.		
	13.	Invitation To Pay Additional Fees mailed January 18, 2005, for PCT Application Number PCT/US2004/003671 filed February 6, 2004, seven pages.		
	14.	Maru, G. B. et al. (1987). "Formation and Persistence of Isoniazid-DNA Adducts in Mouse Tissues," <i>BIOSIS Database, Biosciences Information Service, Database Accession No. PREV198783117667</i> , Abstract, one page.		
	15.	Maru, G. B. et al. (1987). "Formation and Persistence of Isoniazid-DNA Adducts in Mouse Tissues," <i>Human Toxicology</i> 6(2):153-158.		
J	16.	Rescigno, M. et al. (March 2001). "Dendritic Cells, Loaded with Recombinant Bacteria Expressing Tumor Antigens, Induce a Protective Tumor-Specific Response," <i>Clinical Cancer Research</i> 7(Suppl.):865s-870s.		

Examiner Signature		Date Considered	11/7/04
-----------------------	--	--------------------	---------



pa- 950718

Substitute for form 1449/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Application Number	10/773,792
				Filing Date	February 6, 2004
				First Named Inventor	Thomas W. DUBENSKY, Jr.
				Art Unit	1645
				Examiner Name	J. Graser
Sheet	2	of	2	Attorney Docket Number	282172002900


17.	Rescigno, M. et al. (March 2001). "Dendritic Cells, Loaded with Recombinant Bacteria Expressing Tumor Antigens, Induce a Protective Tumor-Specific Response," <i>Medline Database, U.S. National Library of Medicine (NLM), Database Accession No. NLM11300484</i> . Abstract, one page.	
18.	Sashinami, H. et al. (January 2003). "Effective Induction of Acquired Resistance to <i>Listeria monocytogenes</i> by Immunizing Mice With In Vivo-Infected Dendritic Cells," <i>Infection and Immunity</i> 71(1):117-125.	
19.	Sharma, N. et al. (July 1, 2004). "Potent Role of Vaccines Prepared from Macrophages Infected with Live Bacteria in Protection against <i>Mycobacterium tuberculosis</i> and <i>Salmonella typhimurium</i> Infections," <i>Journal of Infectious Diseases</i> 190(1):107-114.	
20.	Svensson, M. et al. (May 1, 1997). "Bone Marrow-Derived Dendritic Cells Can Process Bacteria for MHC-I and MHC-II Presentation to T Cells," <i>The Journal of Immunology</i> 158(9):4229-4236.	
21.	Worgall, S. et al. (July 2001). "Protection Against Pulmonary Infection with <i>Pseudomonas aeruginosa</i> Following Immunization with <i>P. aeruginosa</i> -Pulsed Dendritic Cells," <i>Infection and Immunity</i> 69(7):4521-4527.	

*EXAMINER: Initial if information considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	
--------------------	---	-----------------	---

pa- 950718



hereby certify that this correspondence is being deposited with the U.S. Postal Service as Express Mail, Airbill No. EV 596702514 US, in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

Dated: April 10, 2006

Signature:

Georgina Matos
(Georgina Matos)

Patent

Docket No. 282172002900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:

Thomas W. DUBENSKY, Jr. et al.

Serial No.: 10/773,792

Filing Date: February 6, 2004

For: LISTERIA ATTENUATED FOR ENTRY
INTO NON-PHAGOCYtic CELLS,
VACCINES COMPRISING THE
LISTERIA, AND METHODS OF USE
THEREOF

Examiner: J. Graser

Group Art Unit: 1645

**SUPPLEMENTAL INFORMATION DISCLOSURE
STATEMENT UNDER 37 C.F.R. § 1.97 & 1.98**

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Dear Sir:

Pursuant to 37 C.F.R. §1.97 and § 1.98, Applicants submit for consideration in the above-identified application the documents listed on the attached Form PTO/SB/08a/b. Copies of foreign documents and non-patent literature are submitted herewith. The Examiner is requested to make these documents of record.

Applicants note that the document submitted herewith as "Brockstedt, D. et al. (March 2003). "Recombinant Attenuated *Listeria monocytogenes* Elicits Robust Cellular Immune Response to Tumor-Associated Antigen in *Listeria* Immune Mice," *Proceedings of the American Association for Cancer Research, 94th Annual Meeting*, April 5-9, 2003, Toronto, Ontario, Canada, 44:194, Abstract No. 851, one page" (Ref. No. 16) was previously submitted with the Information Disclosure Statement filed on July 21, 2004, but was incorrectly identified on the Form PTO-1449 filed on that date as "Brockstedt, D. et al. (March 10, 2003). "Recombinant Attenuated *Listeria monocytogenes* Elicits Robust Cellular Immune Response to Tumor-Associated Antigen in *Listeria* Immune Mice," Abstract #851, *posted online at Days of Molecular Symposium* website, one page" (Ref. No. 76) due to inadvertent error.

Applicants would also like to draw the Examiner's attention to the fact that Ref. No. 3 submitted herewith is a translation of Ref. No. 10 (FR 2 686 896) previously submitted on January 6, 2005. Ref. No. 5 submitted herewith is a translation of Ref. No. 14 (WO 99/29884) submitted on January 6, 2005. Ref. No. 6 submitted herewith is a translation of Ref. No. 48 (WO 01/27295) submitted on July 21, 2004.

Applicants would also like to draw the Examiner's attention to the co-pending applications listed below:

Application Serial No. 10/883,599, filed June 30, 2004 by Dubensky, Jr. et al. and
Application Serial No. 11/173,770, filed June 30, 2005 by Dubensky, Jr. et al.

This Supplemental Information Disclosure Statement is submitted:

- ☐ With the application; accordingly, no fee or separate requirements are required.
- ☐ Before the mailing of a first Office Action after the filing of a Request for Continued Examination under § 1.114. However, if applicable, a certification under 37 C.F.R. § 1.97 (e)(1) has been provided.

- ☒ Within three months of the application filing date or before mailing of a first Office Action on the merits; accordingly, no fee or separate requirements are required. However, if applicable, a certification under 37 C.F.R. § 1.97 (e)(1) has been provided.
- ☐ After receipt of a first Office Action on the merits but before mailing of a final Office Action or Notice of Allowance.
- ☐ A fee is required. A check in the amount of __ is enclosed.
- ☐ A fee is required. Accordingly, a Fee Transmittal form (PTO/SB/17) is attached to this submission in duplicate.
- ☐ A Certification under 37 C.F.R. § 1.97(e) is provided above; accordingly, no fee is believed to be due.
- ☐ After mailing of a final Office Action or Notice of Allowance, but before payment of the issue fee.
- ☐ A Certification under 37 C.F.R. § 1.97(e) is provided above and a check in the amount of __ is enclosed.
- ☐ A Certification under 37 C.F.R. § 1.97(e) is provided above and a Fee Transmittal form (PTO/SB/17) is attached to this submission in duplicate.

Applicants would appreciate the Examiner initialing and returning the Form PTO/SB/08a/b, indicating that the information has been considered and made of record herein.

The information contained in this Supplemental Information Disclosure Statement under 37 C.F.R. § 1.97 and § 1.98 is not to be construed as a representation that: (i) a complete search has been made; (ii) additional information material to the examination of this application does not exist; (iii) the information, protocols, results and the like reported by third parties are accurate or enabling; or (iv) the above information constitutes prior art to the subject invention.


Application Serial No. 10/773,792

Patent
Docket No. 282172002900

In the unlikely event that the transmittal form is separated from this document and the Patent and Trademark Office determines that an extension and/or other relief (such as payment of a fee under 37 C.F.R. § 1.17 (p)) is required, Applicants petition for any required relief including extensions of time and authorize the Commissioner to charge the cost of such petition and/or other fees due in connection with the filing of this document to Deposit Account No. 03-1952 referencing 282172002900.

Dated: April 10, 2006

Respectfully submitted,

By 
Alicia J. Hager
Registration No.: 44,140

MORRISON & FOERSTER LLP
755 Page Mill Road
Palo Alto, California 94304-1018
(650) 813-4296



ALTERNATIVE TO PTO/SB/08a/b (07-05)

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Complete if Known			
		Application Number	10/773,792		
		Filing Date	February 6, 2004		
		First Named Inventor	Thomas W. DUBENSKY, Jr.		
		Art Unit	1645		
		Examiner Name	J. Graser		
Sheet	1	of	4	Attorney Docket Number	282172002900

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	1.	US-2005/0249748-A1	11-10-2005	Dubensky Jr. et al.	
	2.	US-2005/0281783-A1	12-22-2005	Kinch et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁵
		Country Code ² -Number ³ -Kind Code ⁴ (if known)	MM-DD-YYYY			
9	3.	FR-2 686 896-A1	08-06-1993	Pasteur Institute		✓
	4.	WO-89/09616-A1	10-19-1989	Symbicom Aktiebolag		
	5.	WO-99/29884-A2	06-17-1999	Von Eichel-Streiber et al.		✓
	6.	WO-01/27295-A1	04-19-2001	Deutsches Krebsforschungszentrum Stiftung Des Offentlichen Rechts		✓
	7.	WO-02/33109-A2, A3	04-25-2002	Biotechnologisk Institut		
	8.	WO-03/083056-A2, A3	10-09-2003	Research Development Foundation		
	9.	WO-2004/011492-A1	02-05-2004	Commonwealth Scientific and Industrial Research Organisation		
	10.	WO-2005/009463-A2, A3	02-03-2005	Cerus Corporation		
	11.	WO-2005/037233-A2, A3	04-28-2005	Medimmune, Inc.		
	12.	WO-2005/071088-A2, A3	08-04-2005	Cerus Corporation		
	13.	WO-2005/092372-A2	10-06-2005	Cerus Corporation et al.		

* EXAMINER: Initial if information considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language translation is attached.


NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	14.	Barnard, J.P. et al. (February 1999). "Vaccination Against Anthrax with Attenuated Recombinant Strains of <i>Bacillus anthracis</i> That Produce Protective Antigen," <i>Infection and Immunity</i> 67(2):562-567.	
	15.	Bielecki, J. et al. (May 10, 1990). " <i>Bacillus subtilis</i> Expressing a Haemolysin Gene from <i>Listeria monocytogenes</i> Can Grow in Mammalian Cells," <i>Nature</i> 345(6271):175-176.	
	16.	Brockstedt, D. et al. (March 2003). "Recombinant Attenuated <i>Listeria monocytogenes</i> Elicits Robust Cellular Immune Response to Tumor-Associated Antigen in <i>Listeria</i> Immune Mice," <i>Proceedings of the American Association for Cancer Research, 94th Annual Meeting</i> , April 5-9, 2003, Toronto, Ontario, Canada, 44:194, Abstract No. 851, one page.	
	17.	Brockstedt, D.G. (Date Unknown). " <i>Listeria</i> -CEA Vaccine-Infected DC for Cancer Therapy," Abstract for Grant No. 1R43CA108026-01 located at http://crisp.cit.nih.gov/crisp/CRISP_LIB.getdoc?testkey=6787426&p_grant_num=1R43C... last visited June 27, 2004, two pages.	
Examiner Signature			Date Considered

pa-1054198

11/10/05

Substitute for form 1449/PTO		Complete if Known	
		Application Number	10/773,792
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Filing Date	February 6, 2004
		First Named Inventor	Thomas W. DUBENSKY, Jr.
		Art Unit	1645
		Examiner Name	J. Graser
Sheet	2	of	4
		Attorney Docket Number	282172002900

18.	Brockstedt, D.G. et al. (August 2005) "Killed but Metabolically Active Microbes: A New Vaccine Paradigm For Eliciting Effector T-Cell Responses and Protective Immunity," <i>Nature Medicine</i> 11(8):853-860.
19.	Brossier, F. et al. (August 1999). "Antigen Delivery by Attenuated <i>Bacillus anthracis</i> : New Prospects in Veterinary Vaccines," <i>Journal of Applied Microbiology</i> 87(2):298-302.
20.	Brown, D.P et al. (May 1988). "Site-Specific Integration in <i>Saccharopolyspora erythraea</i> and Multisite Integration in <i>Streptomyces lividans</i> of Actinomycete Plasmid pSE101," <i>J. Bacteriology</i> 170(5):2287-2295.
21.	Cohen, S. et al. (August 2000). "Attenuated Nontoxigenic and Nonencapsulated Recombinant <i>Bacillus anthracis</i> Spore Vaccines Protect Against Anthrax," <i>Infection and Immunity</i> 68(8):4549-4558.
22.	Conradt, P. et al. (1999). "Cytolytic T-Cell Responses to Human Dendritic Cells and Macrophages Infected with <i>Mycobacterium bovis</i> BCG and Recombinant BCG Secreting Listeriolysin," <i>Microbes Infect.</i> 1:753-764.
23.	Dubensky, T.W. (Date Unknown). "Listeria-Based Vaccines for Ovarian Cancer Therapy," Abstract for Grant No. 1R43CA101421-01 located at < http://crisp.cit.nih.gov/crisp/CRISP_LIB.getdoc?testkey=6645288&p_grant_num=1R43CA... > last visited November 3, 2004, two pages.
24.	Dubensky, T.W. (Date Unknown). "Psoralen-Killed, Metabolically-Active Anthrax Vaccine," Abstract for Grant No. 1U01AI061199-01 located at < http://crisp.cit.nih.gov/crisp/CRISP_LIB.getdoc?testkey=6818020&p_grant_num=1U01AI... > last visited November 3, 2004, two pages.
25.	Dubensky, T.W. (Date Unknown). "Listeria Immunotherapy for Pancreatic and Ovarian Cancer," Abstract for Grant No. 2R44CA101421-02 located at < http://crisp.cit.nih.gov/crisp/CRISP_LIB.getdoc?testkey=6992210&p_grant_num=2R44C... > last visited December 7, 2005, two pages.
26.	Dubensky, T.W. (Date Unknown). "Psoralen-Killed, Metabolically-Active Anthrax Vaccine," Abstract for Grant No. 5U01AI061199-01 located at < http://crisp.cit.nih.gov/crisp/CRISP_LIB.getdoc?testkey=6916362&p_grant_num=5U01A... > last visited December 7, 2005, two pages.
27.	Friedman, R.S. et al. (November 2000). "Induction of Human Immunodeficiency Virus (HIV)-Specific CD8 T-Cell Responses by <i>Listeria monocytogenes</i> and a Hyperattenuated <i>Listeria</i> Strain Engineered to Express HIV Antigens," <i>Journal of Virology</i> 74(21):9987-9993.
28.	Giedlin, M. et al. (Date Unknown). "The Living Dead: Vaccines Against Microbial Pathogens Based on Psoralen-Killed Metabolically Active DNA Repair Mutants," Abstract 189 (H) located at < http://www.asmbiodefense.org/2004tueabs.asp >, last visited November 5, 2004, one page.
29.	Giedlin, M.A. (Date Unknown). "Use of <i>Listeria</i> as Colon Cancer Vaccine Adjuvants," Abstract for Grant No. 1R43CA101378-01 located at < http://crisp.cit.nih.gov/crisp/CRISP_LIB.getdoc?testkey=6645212&p_grant_num=1R43CA... > last visited November 3, 2004, two pages.
30.	Giedlin, M.A. (Date Unknown). "Listeria-Based Ovarian Cancer Polyepitope Vaccines," Abstract for Grant No. 1R43CA109868-01A1 located at < http://crisp.cit.nih.gov/crisp/CRISP_LIB.getdoc?testkey=6932934&p_grant_num=1R43C... > last visited December 7, 2005, two pages.
31.	Giedlin, M.A. et al. (March 2003). "Therapeutic Immunization with Attenuated Recombinant <i>Listeria monocytogenes</i> Prolongs Survival in a Murine Transplant Model of Melanoma," <i>Proceedings of the American Association for Cancer Research, 94th Annual Meeting</i> , April 5-9, 2003, Toronto, Ontario, Canada, 44:194, Abstract No. 850, one page.
32.	Glomski, I.J. et al. (December 2003). " <i>Listeria monocytogenes</i> Mutants That Fail to Compartmentalize Listeriolysin O Activity Are Cytotoxic, Avirulent, and Unable To Evade Host Extracellular Defenses," <i>Infect. Immun.</i> 71(12):6754-6765.

Examiner Signature		Date Considered	11/17/05
pa- 1054198			

Substitute for form 1449/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Application Number	10/773,792
		Filing Date	February 6, 2004
		First Named Inventor	Thomas W. DUBENSKY, Jr.
		Art Unit	1645
		Examiner Name	J. Graser
		Attorney Docket Number	282172002900
Sheet	3	of	4

33.	Guerry, P. et al. (February 1994). "Development and Characterization of <i>recA</i> Mutants of <i>Campylobacter jejuni</i> for Inclusion in Attenuated Vaccines," <i>Infection and Immunity</i> 62(2):426-432.
34.	Gunn, G.R. et al. (2002). "Recombinant Intra-Cellular Bacteria as Carriers for Tumor Antigens" Chapter 14 In <i>Vaccine Delivery Strategies</i> , Dietrich, G. et al. eds., Horizon Scientific Press: UK. pp. 315-348.
35.	Guzman, C.A. et al. (June 1998). "Attenuated <i>Listeria monocytogenes</i> Carrier Strains Can Deliver an HIV-1 gp120 T Helper Epitope to MHC Class II-Restricted Human CD4 ⁺ T Cells," <i>European Journal of Immunology</i> 28(6):1807-1814.
36.	Huang, A.T.C. et al. (May 13, 1994). "Role of Bone Marrow-Derived Cells in Presenting MHC Class I-Restricted Tumor Antigens," <i>Science</i> 264:961-965.
37.	International Search Report issued for PCT Application No. PCT/US2004/003671 filed February 6, 2004, mailed April 13, 2005, 12 pages.
38.	International Search Report issued for PCT Application No. PCT/US2005/002987 filed February 2, 2005, mailed January 19, 2006, 11 pages.
39.	Kiessling, A. et al. (December 1, 2002). "Prostate Stem Cell Antigen: Identification of Immunogenic Peptides and Assessment of Reactive CD8 ⁺ T Cells in Prostate Cancer Patients," <i>Int. J. Cancer</i> 102(4):390-397.
40.	Lampson, L.A. et al. (January 1, 1993). "Exploiting the <i>lacZ</i> Reporter Gene for Quantitative Analysis of Disseminated Tumor Growth within the Brain: Use of the <i>lacZ</i> Gene Product as a Tumor Antigen, for Evaluation of Antigenic Modulation, and to Facilitate Image Analysis of Tumor Growth <i>in Situ</i> ," <i>Cancer Research</i> 53(1):176-182.
41.	Lebrun, M. et al. (August 1996). "Internalin Must be on the Bacterial Surface to Mediate Entry of <i>Listeria monocytogenes</i> into Epithelial Cells," <i>Molecular Microbiology</i> 21(3):579-592.
42.	Lutz, M.B. et al. (1999). "An Advanced Culture Method For Generating Large Quantities of Highly Pure Dendritic Cells From Mouse Bone Marrow," <i>J. Immunol. Methods</i> 223(1):77-92.
43.	Mata, M. et al. (January 8, 2001). "Evaluation of a Recombinant <i>Listeria monocytogenes</i> Expressing an HIV Protein that Protects Mice Against Viral Challenge," <i>Vaccine</i> 19(11-12):1435-1445.
44.	McCloy, E.W. (1951). "Studies on a Lysogenic <i>Bacillus</i> Strain. I. A Bacteriophage Specific for <i>Bacillus anthracis</i> ," <i>J. Hyg.</i> 49:114-125.
45.	Mérino, D. et al. (2002). "A Hypermutator Phenotype Attenuates the Virulence of <i>Listeria monocytogenes</i> in a Mouse Model," <i>Molecular Microbiology</i> 44(3):877-887.
46.	Mollet, B. et al. (July 1993). "Directed Genomic Integration, Gene Replacement, and Integrative Gene Expression in <i>Streptococcus thermophilus</i> ," <i>J. Bacteriology</i> 175(14):4315-4324.
47.	Paglia, P. et al. (June 1997). "The Defined Attenuated <i>Listeria monocytogenes</i> Δ mpl2 Mutant is an Effective Oral Vaccine Carrier to Trigger a Long-Lasting Immune Response Against a Mouse Fibrosarcoma," <i>Eur. J. Immunol.</i> 27(6):1570-1575.
48.	Reiter, R.E. et al. (February 1998). "Prostate Stem Cell Antigen: A Cell Surface Marker Overexpressed in Prostate Cancer," <i>Proc. Natl. Acad. Sci. USA</i> 95:1735-1740.
49.	Scheirlinck, T. et al. (September 1989). "Integration and Expression of α -Amylase and Endoglucanase Genes in the <i>Lactobacillus plantarum</i> Chromosome," <i>Applied and Environmental Microbiology</i> 55(9):2130-2137.
50.	Smith, B.T. et al. (January 2002). "Localization of UvrA and Effect of DNA Damage on the Chromosome of <i>Bacillus subtilis</i> ," <i>Journal of Bacteriology</i> 184(2):488-493.
51.	Smith, G.A. et al. (September 1995). "Asymmetric Distribution of the <i>Listeria monocytogenes</i> ActA Protein is Required and Sufficient to Direct Actin-Based Motility," <i>Molecular Microbiology</i> 17(5):945-951.
52.	Snyder, J.T. et al. (July 2004). "Protection Against Lethal Vaccinia Virus Challenge in HLA-A2 Transgenic Mice by Immunization with a Single CD8 ⁺ T-Cell Peptide Epitope of Vaccinia and Variola Viruses," <i>J. Virol.</i> 78(13):7052-7060.

Examiner
Signature
pa- 1054198

Date
Considered


11/7/05

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/773,792
				Filing Date	February 6, 2004
				First Named Inventor	Thomas W. DUBENSKY, Jr.
				Art Unit	1645
				Examiner Name	J. Graser
Sheet	4	of	4	Attorney Docket Number	282172002900

53.	Stahl, M.L. et al. (May 1984). "Replacement of the <i>Bacillus subtilis</i> Subtilisin Structural Gene with an In Vitro-Derived Deletion Mutation," <i>J. Bacteriology</i> 158(2):411-418.
54.	Strugnell, R.A. et al. (1990). "Stable Expression of Foreign Antigens from the Chromosome of <i>Salmonella typhimurium</i> Vaccine Strains," <i>Gene</i> 88(1):57-63.
55.	Svensson, M. et al. (June 1996). "Dendritic Cells Can Process Viable Bacteria and Present Bacterial Antigens on MHC-1 Molecules," <i>Scandinavian Journal of Immunology</i> 43(6):723. Abstract No. 121.
56.	Van Pinxteren, L.A.H. et al. (2000). "Control of Latent <i>Mycobacterium tuberculosis</i> Infection is Dependent on CD8 T cells," <i>Eur. J. Immunol.</i> 30:3689-3698.
57.	Welch, M.D. et al. (July 3, 1998). "Interaction of Human Arp2/3 Complex and the <i>Listeria monocytogenes</i> ActA Protein in Actin Filament Nucleation," <i>Science</i> 281:105-108.
58.	Winterling, K.W. et al. (April 1998). "The <i>Bacillus subtilis</i> DinR Binding Site: Redefinition of the Consensus Sequence," <i>J. Bacteriol.</i> 180(8):2201-2211.
59.	Wirth, R. et al. (March 1986). "Highly Efficient Protoplast Transformation System for <i>Streptococcus faecalis</i> and a New <i>Escherichia coli</i> - <i>S. faecalis</i> Shuttle Vector," <i>J. Bacteriol.</i> 165(3):831-836.
60.	Written Opinion issued for PCT Application No. PCT/US2004/003429 filed February 6, 2004, mailed December 7, 2004, 9 pages.
61.	Written Opinion issued for PCT Application No. PCT/US2004/003671 filed February 6, 2004, mailed April 13, 2005, 15 pages.
62.	Written Opinion issued for PCT Application No. PCT/US2005/002987 filed February 2, 2005, mailed January 19, 2006, 9 pages.

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	11/17/04
--------------------	---	-----------------	----------

pa-1054198



04-25-05

JFW

PTO/SB/21 (09-04)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM (to be used for all correspondence after initial filing)		Application Number	10/773,792
		Filing Date	February 6, 2004
		First Named Inventor	Thomas W. DUBENSKY, Jr.
		Art Unit	1645
		Examiner Name	J. Graser
Total Number of Pages in This Submission	6 + 7 Refs.	Attorney Docket Number	282172002900

ENCLOSURES (Check all that apply)		
<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment/Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input checked="" type="checkbox"/> Information Disclosure Statement (Supplemental - 3 pages) <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Reply to Missing Parts/Incomplete Application <input type="checkbox"/> Reply to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney; Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____ <input type="checkbox"/> Landscape Table on CD	<input type="checkbox"/> After Allowance Communication to TC <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): 1. Form PTO/SB/08a/b + copy (2 pages) 2. 7 References 3. Return Receipt Postcard
Remarks		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT			
Firm Name	MORRISON & FOERSTER LLP (Customer No. 25226)		
Signature			
Printed name	Alicia J. Hager		
Date	April 21, 2005	Reg. No.	44,140

I hereby certify that this correspondence is being deposited with the U.S. Postal Service as Express Mail, Airbill No. EV336621693US, in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.	
Dated: April 21, 2005	Signature: (Georgina Matos)

I hereby certify that this correspondence is being deposited with the U.S. Postal Service as Express Mail, Airbill No. EV336621693US, in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

Dated: April 21, 2005

Signature:

Georgina Matos
(Georgina Matos)



Patent

Docket No. 282172002900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:

Thomas W. DUBENSKY, Jr. et al.

Serial No.: 10/773,792

Filing Date: February 6, 2004

For: LISTERIA ATTENUATED FOR ENTRY
INTO NON-PHAGOCYTOTIC CELLS,
VACCINES COMPRISING THE
LISTERIA, AND METHODS OF USE
THEREOF

Examiner: J. Graser

Group Art Unit: 1645

**SUPPLEMENTAL INFORMATION DISCLOSURE
STATEMENT UNDER 37 C.F.R. § 1.97 & 1.98**

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Dear Sir:

Pursuant to 37 C.F.R. § 1.97 and § 1.98, Applicants submit for consideration in the above-identified application the documents listed on the attached Form PTO/SB/08a/b. Copies of the documents are also submitted herewith. The Examiner is requested to make these documents of record.

Pursuant to 37 C.F.R. § 1.704(d), I hereby certify that each item of information contained in this Supplemental Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart application and that this communication was not received by any individual designated in § 1.56(c) more than thirty days prior to the filing of this Supplemental Information Disclosure Statement.

The documents listed on the attached Form PTO/SB/08a/b were cited in an International Search Report and/or Written Opinion mailed on April 7, 2005, directed to a counterpart international or foreign application. A certification under 37 C.F.R. § 1.97(e)(1) follows:

I hereby certify that each item of information contained in this Supplemental Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Supplemental Information Disclosure Statement.

This Supplemental Information Disclosure Statement is submitted:

- ☐ With the application; accordingly, no fee or separate requirements are required.
- ☐ Before the mailing of a first Office Action after the filing of a Request for Continued Examination under § 1.114. However, if applicable, a certification under 37 C.F.R. § 1.97 (e)(1) has been provided.
- ☒ Within three months of the application filing date or before mailing of a first Office Action on the merits; accordingly, no fee or separate requirements are required. However, if applicable, a certification under 37 C.F.R. § 1.97 (e)(1) has been provided.
- ☐ After receipt of a first Office Action on the merits but before mailing of a final Office Action or Notice of Allowance.
 - ☐ A fee is required. A check in the amount of __ is enclosed.
 - ☐ A fee is required. Accordingly, a Fee Transmittal form (PTO/SB/17) is attached to this submission in duplicate.
 - ☐ A Certification under 37 C.F.R. § 1.97(e) is provided above; accordingly, no fee is believed to be due.
- ☐ After mailing of a final Office Action or Notice of Allowance, but before payment of the issue fee.
 - ☐ A Certification under 37 C.F.R. § 1.97(e) is provided above and a check in the amount of __ is enclosed.
 - ☐ A Certification under 37 C.F.R. § 1.97(e) is provided above and a Fee Transmittal form (PTO/SB/17 is attached to this submission in duplicate.)

Applicants would appreciate the Examiner initialing and returning the Form PTO/SB/08a/b, indicating that the information has been considered and made of record herein.


The information contained in this Supplemental Information Disclosure Statement under 37 C.F.R. § 1.97 and § 1.98 is not to be construed as a representation that: (i) a complete search has been made; (ii) additional information material to the examination of this application does not exist; (iii) the information, protocols, results and the like reported by third parties are accurate or enabling; or (iv) the above information constitutes prior art to the subject invention.

In the unlikely event that the transmittal form is separated from this document and the Patent and Trademark Office determines that an extension and/or other relief (such as payment of a fee under 37 C.F.R. § 1.17 (p)) is required, Applicants petition for any required relief including extensions of time and authorize the Commissioner to charge the cost of such petition and/or other fees due in connection with the filing of this document to Deposit Account No. 03-1952 referencing 282172002900.

Dated: April 21, 2005


Respectfully submitted,

By


Alicia J. Hager

Registration No.: 44,140

MORRISON & FOERSTER LLP
755 Page Mill Road
Palo Alto, California 94304-1018
(650) 813-4296



ALTERNATIVE TO PTO/SB/08a/b (08-03)

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)			Complete if Known		
			Application Number	10/773,792	
			Filing Date	February 6, 2004	
			First Named Inventor	Thomas W. DUBENSKY, Jr.	
			Art Unit	1645	
			Examiner Name	J. Graser	
Sheet	1	of	1	Attorney Docket Number	282172002900

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				
	1.	WO-98/33386-A1	08-06-1998	Vanderbilt University		
	2.	WO-00/09156-A1	02-24-2000	Loma Linda University		

*EXAMINER: Initial if information considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	3.	Black, C.G. et al. (February 16, 1998). "Absence of an SOS-like System in <i>Neisseria gonorrhoeae</i> ," <i>Gene</i> 208:61-66.	
	4.	Ferguson, L.R. et al. (1987). "Frameshift Mutagenesis by Nitracrine Analogues in Wild-Type <i>uvrB polA</i> and <i>recA</i> Strains of <i>Salmonella typhimurium</i> With and Without Plasmid pKM101," <i>Mutation Research</i> 184:13-21.	
	5.	Gentschev, I. et al. (September 29, 2000). "Delivery of Protein Antigens and DNA by Virulence-Attenuated Strains of <i>Salmonella typhimurium</i> and <i>Listeria monocytogenes</i> ," <i>Journal of Biotechnology</i> 83:19-26.	
	6.	International Search Report for PCT Application No. PCT/US2004/023881 filed on July 23, 2004, mailed April 7, 2005, 10 pages.	
	7.	Written Opinion for PCT Application No. PCT/US2004/023881 filed on July 23, 2004, mailed April 7, 2005, 11 pages.	

*EXAMINER: Initial if information considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	11/17/07
-----------------------	--	--------------------	----------

pa-973660



1-10-05

TFW

PATENT
Docket No. 282172002900

CERTIFICATE OF MAILING BY "FIRST CLASS MAIL"

I hereby certify that this correspondence is being deposited with the U.S. Postal Service as Express Mail, Airbill No. EV336621835US, in a box addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

Dated: January 6, 2005

Signature:

Georgina Matos (Georgina Matos)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the application of:

Thomas W. DUBENSKY, Jr. et al.

Serial No.: 10/773,792

Filing Date: February 6, 2004

For: LISTERIA ATTENUATED FOR ENTRY
INTO NON-PHAGOCYtic CELLS,
VACCINES COMPRISING THE
LISTERIA, AND METHODS OF USE
THEREOF

Examiner: Not Yet Assigned

Group Art Unit: 1645

**SUPPLEMENTAL INFORMATION DISCLOSURE
STATEMENT UNDER 37 C.F.R. § 1.97 & 1.98**

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Dear Sir:

Pursuant to 37 C.F.R. § 1.97 and § 1.98, Applicants submit for consideration in the above-identified application the documents listed on the attached Form PTO-1449. Copies of foreign documents and non-patent literature are submitted herewith. The Examiner is requested to make these documents of record in the application.

This Supplemental Information Disclosure Statement is submitted:

- ☐ With the application; accordingly, no fee or separate requirements are required.
- ☐ Before the mailing of a first Office Action after the filing of a Request for Continued Examination under § 1.114. However, if applicable, a certification under 37 C.F.R. § 1.97(e)(1) has been provided.
- ☒ Within three months of the application filing date or before mailing of a first Office Action on the merits; accordingly, no fee or separate requirements are required.
- ☐ After receipt of a first Office Action on the merits but before mailing of a final Office Action or Notice of Allowance.
 - ☐ A fee is required. A check in the amount of ___ is enclosed.
 - ☐ A fee is required. Accordingly, a Fee Transmittal form (PTO/SB/17) is attached to this submission in duplicate.
 - ☐ A Certification under 37 C.F.R. § 1.97(e) is provided above; accordingly, no fee is believed to be due.
- ☐ After mailing of a final Office Action or Notice of Allowance, but before payment of the issue fee.
 - ☐ A Certification under 37 C.F.R. § 1.97(e) is provided above and a check in the amount of ___ is enclosed.
 - ☐ A Certification under 37 C.F.R. § 1.97(e) is provided above and a Fee Transmittal form (PTO/SB/17 is attached to this submission in duplicate.)

Applicants would appreciate the Examiner initialing and returning the Form PTO-1449, indicating that the information has been considered and made of record herein.

The information contained in this Supplemental Information Disclosure Statement under 37 C.F.R. § 1.97 and § 1.98 is not to be construed as a representation that: (i) a complete search has been made; (ii) additional information material to the examination of this application does not exist; (iii) the information, protocols, results and the like reported by third parties are accurate or enabling; or (iv) the above information constitutes prior art to the subject invention.


In the unlikely event that the transmittal form is separated from this document and the Patent Office determines that an extension and/or other relief (such as payment of a fee under 37 C.F.R. §1.17(p)) is required, Applicants petition for any required relief including extensions of time and authorize the Commissioner to charge the cost of such petitions and/or other fees due in connection with the filing of this document to Deposit Account No. 03-1952 referencing 282172002900. However, the Commissioner is not authorized to charge the cost of the issue fee to the Deposit Account.

Dated: January 6, 2005

Respectfully submitted,

By: 
Alicia J. Hager
Registration No. 44,140

Morrison & Foerster LLP
755 Page Mill Road
Palo Alto, California 94304-1018
Telephone: (650) 813-4296
Facsimile: (650) 494-0792



PTO/SB/21 (09-04)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM (to be used for all correspondence after initial filing)	Application Number	10/773,792	
	Filing Date	February 6, 2004	
	First Named Inventor	Thomas W. DUBENSKY, Jr.	
	Art Unit	1645	
	Examiner Name	Not Yet Assigned	
Total Number of Pages in This Submission	16 + 73 Refs.	Attorney Docket Number	282172002900

ENCLOSURES (Check all that apply)		
<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment/Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input checked="" type="checkbox"/> Information Disclosure Statement (Supplemental - 3 pages) <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Reply to Missing Parts/Incomplete Application <input type="checkbox"/> Reply to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____ <input type="checkbox"/> Landscape Table on CD	<input type="checkbox"/> After Allowance Communication to TC <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): 1. Form PTO-1449 + copy (12 pages) 2. 73 References 3. Return Receipt Postcard
<div>Remarks</div>		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT			
Firm Name	MORRISON & FOERSTER LLP (Customer No. 25226)		
Signature			
Printed name	Alicia J. Hager		
Date	January 6, 2005	Reg. No.	44,140

I hereby certify that this correspondence is being deposited with the U.S. Postal Service as Express Mail, Airbill No. EV336621835US, in a box addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.	
Dated: January 6, 2005	Signature: (Georgina Matos)

Form PTO-1449 INFORMATION DISCLOSURE CITATION IN AN APPLICATION <i>(Use several sheets if necessary)</i>	Docket Number 282172002900	Application Number 10/773,792
	Applicant Thomas W. DUBENSKY, Jr. et al.	
	Filing Date February 6, 2004	Group Art Unit 1645
	Mailing Date January 6, 2005	

U.S. PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Name	Class	Subclass	Filing Date If Appropriate
	1.	03/07/2002	2002/0028432	Cook et al.			
	2.	12/05/2002	2002/0182581	Cook et al.			
	3.	09/16/2004	2004/0180321	Cook et al.			
	4.	10/07/2004	2004/0197343	Dubensky, JR. et al.			
	5.	01/09/2001	6,171,777	Cook et al.			
	6.	01/23/2001	6,177,441	Cook et al.			
	7.	06/25/2002	6,410,219	Cook et al.			
	8.	01/27/2004	6,682,729	Powell et al.			
	9.	03/23/2004	6,709,810	Cook et al.			

FOREIGN PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Country	Class	Subclass	Translation YES NO
	10.	08/06/1993	FR 2 686 896	France			Abstract
	11.	08/05/1993	WO 93/15212	WIPO			YES
	12.	11/07/1996	WO 96/34631	WIPO			
	13.	12/19/1996	WO 96/39818	WIPO			
	14.	06/17/1999	WO 99/29884	WIPO			
	15.	07/15/2000	WO 99/34839	WIPO			
	16.	10/17/2002	WO 02/20982	WIPO			
	17.	10/07/2004	WO 04/084936	WIPO			
	18.	12/23/2004	WO 04/110481	WIPO			

EXAMINER:


DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

Form PTO-1449 INFORMATION DISCLOSURE CITATION IN AN APPLICATION <i>(Use several sheets if necessary)</i>		Docket Number 282172002900	Application Number 10/773,792
		Applicant Thomas W. DUBENSKY, Jr. et al.	
		Filing Date February 6, 2004	Group Art Unit 1645
		Mailing Date January 6, 2005	
OTHER DOCUMENTS <i>(including author, title, Date, Pertinent Pages, Etc.)</i>			
Examiner Initials	Ref. No.	Title	
	19.	Barry, R.A. et al. (April 1992). "Pathogenicity and Immunogenicity of <i>Listeria monocytogenes</i> Small-Plaque Mutants Defective for Intracellular Growth and Cell-to-Cell Spread," <i>Infection and Immunity</i> 60(4):1625-1632.	
	20.	Bast, R.C. et al. (March 1975). "Antitumor Activity of Bacterial Infection. I. Effect of <i>Listeria monocytogenes</i> on Growth of a Murine Fibrosarcoma," <i>Journal of the National Cancer Institute</i> 54(3):749-756.	
	21.	Bast, R.C. et al. (March 1975). "Antitumor Activity of Bacterial Infection. II. Effect of <i>Listeria monocytogenes</i> on Growth of a Guinea Pig Hepatoma," <i>Journal of the National Cancer Institute</i> 54(3):757-761.	
	22.	Bergmann, B. et al. (February 2002). "InlA- but not InlB-mediated Internalization of <i>Listeria monocytogenes</i> by Non-Phagocytic Mammalian Cells Needs the Support of Other Internalins," <i>Molecular Microbiology</i> 43(3):557-570.	
	23.	Boon, T. et al. (1994). "Tumor Antigens Recognized by T Lymphocytes," <i>Annu. Rev. Immunol.</i> 12:337-365.	
	24.	Bouwer, H.G.A. et al. (April 14, 2003). "Recombinant <i>L. monocytogenes</i> as a Vaccine For Stimulation of Anti-Tumor Responses," (Abstract for the 90th Anniversary Meeting of the American Association of Immunologists, Denver, CO May 6 -10, 2003) <i>FASEB Journal</i> , 17(7):C330-331, Abstract 162.17.	
	25.	Braun, L. et al. (October 1999). "The 213-amino-acid Leucine-rich Repeat Region of the <i>Listeria monocytogenes</i> InlB Protein is Sufficient for Entry into Mammalian Cells, Stimulation of PI 3-Kinase and Membrane Ruffling," <i>Molecular Microbiology</i> 34(1):10-23.	
	26.	Bridges, B.A. et al. (August 1979). "Inactivation of <i>Escherichia coli</i> by Near-Ultraviolet Light and 8-Methoxypsoralen: Different Responses of Strains B/r and K-12," <i>Journal of Bacteriology</i> 139(2):454-459.	
	27.	Brockstedt, D. et al. (July 2003). "Recombinant Attenuated <i>Listeria monocytogenes</i> Elicits Robust Cellular Immune Response to Tumor-Associated Antigen in <i>Listeria</i> Immune Mice," (Abstract for the 94th Annual Meeting of the American Association for Cancer Research, Washington DC, USA, July 11-14, 2003) <i>Proceedings of the American Association For Cancer Research Annual Meeting</i> 44(2):168, Abstract No. 851.	
	28.	Brockstedt, D.G. et al. (September 21, 2004). " <i>Listeria</i> -based Cancer Vaccines That Segregate Immunogenicity From Toxicity," <i>Proc. Natl. Acad. Sci. USA</i> Vol. 101(38):13832-13837.	
	29.	Brooks, P.C. et al. (August 2001). "Identification of Some DNA Damage-Inducible Genes of <i>Mycobacterium tuberculosis</i> : Apparent Lack of Correlation with LexA Binding," <i>Journal of Bacteriology</i> 183(15):4459-4467.	
EXAMINER:		DATE CONSIDERED: 11/17/04	
EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.			
PTO/SB/ 08 (2-92) pa- 901679		Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE	

Form PTO-1449		Docket Number 282172002900	Application Number 10/773,792
INFORMATION DISCLOSURE CITATION IN AN APPLICATION (Use several sheets if necessary)		Applicant Thomas W. DUBENSKY, Jr. et al.	
		Filing Date February 6, 2004	Group Art Unit 1645
		Mailing Date January 6, 2005	

30.	Cole, R.S. (September 1971). "Inactivation of <i>Escherichia coli</i> , F' Episomes at Transfer, and Bacteriophage Lambda by Psoralen Plus 360-nm Light: Significance of Deoxyribonucleic Acid Cross-Links," <i>Journal of Bacteriology</i> 107(3):846-852.
31.	Cole, R.S. et al. (1975). "Repair of Cross-Linked DNA in <i>Escherichia coli</i> " Chapter 66 <i>In Basic Life Sciences: Molecular Mechanisms For Repair of DNA</i> Part B, Hollaender, A. ed. Plenum Press, pp 487-495.
32.	Drams, S. et al. (May 1997). "Identification of Four New Members of the Internalin Multigene Family of <i>Listeria monocytogenes</i> EGD," <i>Infection and Immunity</i> 65(5):1615-1625.
33.	Drevets, D.A. (July 1999). "Dissemination of <i>Listeria monocytogenes</i> by Infected Phagocytes," <i>Infection and Immunity</i> 67(7):3512-3517.
34.	Drevets, D.A. et al. (November 1995). " <i>Listeria monocytogenes</i> Infects Human Endothelial Cells by Two Distinct Mechanisms," <i>Infection and Immunity</i> 63(11):4268-4276.
35.	Dustoor, M.M. et al. (January 1979). "Antitumor Activity of <i>Listeria monocytogenes</i> on a Guinea Pig Fibrosarcoma," <i>Infection and Immunity</i> 23(1):54-60.
36.	Engelbrecht, F. et al. (1996). "A New PrfA-Regulated Gene of <i>Listeria monocytogenes</i> Encoding a Small, Secreted Protein Which Belongs to the Family of Internalins," <i>Molecular Microbiology</i> 21(4):823-837.
37.	Fong, L. et al. (March 15, 2001). "Dendritic Cells Injected Via Different Routes Induce Immunity in Cancer Patients," <i>Journal of Immunology</i> 166:4254-4259.
38.	Fong, L. et al. (November 2002). "Productive Infection of Plasmacytoid Dendritic Cells with Human Immunodeficiency Virus Type 1 Is Triggered by CD40 Ligation," <i>Journal of Virology</i> 76(21):11033-11041.
39.	Frankel, F.R. et al. (October 1994). "Delivery of HIV Antigens Using <i>Listeria monocytogenes</i> as a Live Vaccine Vector," <u>Abstracts of Papers Presented at the 1994 Meeting on Molecular Approaches to the Control of Infectious Diseases (October 5 - 9, 1994)</u> Cold Spring Harbor Laboratory Press: Cold Spring Harbor, NY pg. 56.
40.	Frankel, F.R. et al. (1995). "Induction of Cell-Mediated Immune Responses to Human Immunodeficiency Virus Type 1 Gag Protein by Using <i>Listeria monocytogenes</i> as a Live Vaccine Vector," <i>The Journal of Immunology</i> 155:4775-4782.
41.	Freitag, N.E. et al. (April 1999). "Examination of <i>Listeria monocytogenes</i> Intracellular Gene Expression by Using the Green Fluorescent Protein of <i>Aequorea victoria</i> ," <i>Infection and Immunity</i> 67(4):1844-1852.
42.	Gaillard, J-L. et al. (February 1996). "The <i>inlAB</i> Locus Mediates the Entry of <i>Listeria monocytogenes</i> into Hepatocytes In Vivo," <i>Journal of Experimental Medicine</i> 183(2):359-369.
43.	GenBank Accession No. AE017040 created on May 1, 2003, located at < http://www.ncbi.nlm.nih.gov > last visited on November 15, 2004, 159 pages.

EXAMINER:		DATE CONSIDERED:	11/17/04
EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.			

PTO/SB/ 08 (2-92) Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
 pa- 901679

Form PTO-1449 INFORMATION DISCLOSURE CITATION IN AN APPLICATION (Use several sheets if necessary)		Docket Number 2821 72002900	Application Number 10/773,792
		Applicant Thomas W. DUBENSKY, Jr. et al.	
		Filing Date February 6, 2004	Group Art Unit 1645
		Mailing Date January 6, 2005	
<div><div></div><div>44. GenBank Accession No. AL591824 created on July 18, 2002, located at <http://www.ncbi.nlm.nih.gov> last visited on November 15, 2004, two pages.</div></div>			
<div><div></div><div>45. GenBank Accession No. AL591974 created on June 6, 2002, located at <http://www.ncbi.nlm.nih.gov> last visited on November 15, 2004, 87 pages.</div></div>			
<div><div></div><div>46. GenBank Accession No. AL591975 created on June 6, 2002, located at <http://www.ncbi.nlm.nih.gov> last visited on November 15, 2004, 157 pages.</div></div>			
<div><div></div><div>47. GenBank Accession No. M24199 created on October 22, 1993, located at <http://www.ncbi.nlm.nih.gov> last visited on November 15, 2004, three pages.</div></div>			
<div><div></div><div>48. GenBank Accession No. M67471 created on April 26, 1993, located at <http://www.ncbi.nlm.nih.gov> last visited on November 15, 2004, four pages.</div></div>			
<div><div></div><div>49. Giedlin, M.A. et al. (July 2003). "Therapeutic Immunization with Attenuated Recombinant <i>Listeria monocytogenes</i> Prolongs Survival in a Murine Transplant Model of Melanoma," (Abstract for the 94th Annual Meeting of the American Association for Cancer Research, Washington DC, USA, July 11-14, 2003) <i>Proceedings of the American Association For Cancer Research Annual Meeting</i> 44(2):167-168, Abstract No. 850.</div></div>			
<div><div></div><div>50. Gouin, E. et al. (August 1994). "The Virulence Gene Cluster of <i>Listeria monocytogenes</i> Is Also Present in <i>Listeria ivanovii</i>, an Animal Pathogen, and <i>Listeria seeligeri</i>, a Nonpathogenic Species," <i>Infection and Immunity</i> 62(8):3550-3553.</div></div>			
<div><div></div><div>51. Greiffenberg, L. et al. (December 1, 1997). "<i>Listeria monocytogenes</i>-infected Human Umbilical Vein Endothelial Cells: Internalin-Independent Invasion, Intracellular Growth, Movement, and Host Cell Responses," <i>FEMS Microbiology Letters</i> 157:163-170.</div></div>			
<div><div></div><div>52. Greiffenberg, L. et al. (November 1998). "Interaction of <i>Listeria monocytogenes</i> with Human Brain Microvascular Endothelial Cells: In1B-Dependent Invasion, Long-Term Intracellular Growth, and Spread from Macrophages to Endothelial Cells," <i>Infection and Immunity</i> 66(11):5260-5267.</div></div>			
<div><div></div><div>53. Hansen, M.T. (1982). "Sensitivity of <i>Escherichia coli</i> <i>acrA</i> Mutants to Psoralen Plus Near-Ultraviolet Radiation," <i>Mutation Research</i> 106:209-216.</div></div>			
<div><div></div><div>54. Hartman, P.E. et al. (1996). "Breakthrough of Ultraviolet Light From Various Brands of Fluorescent Lamps: Lethal Effects on DNA Repair-Defective Bacteria," <i>Environmental and Molecular Mutagenesis</i> 27:306-313.</div></div>			
<div><div></div><div>55. Higgins, D.E. et al. (1999). "Delivery of Protein to the Cytosol of Macrophages using <i>Escherichia coli</i> K-12," <i>Molecular Microbiology</i> 31(6):1631-1641.</div></div>			
<div><div></div><div>56. Horton, R.M. et al. (1990). "Gene Splicing by Overlap Extension: Tailor-Made Genes Using the Polymerase Chain Reaction," <i>Biotechniques</i> 8(5):528-535.</div></div>			
EXAMINER:		DATE CONSIDERED:	
EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.			
PTO/SB/ 08 (2-92) pa- 901679		Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE	

Form PTO-1449		Docket Number 282172002900	Application Number 10/773,792
INFORMATION DISCLOSURE CITATION IN AN APPLICATION (Use several sheets if necessary)		Applicant Thomas W. DUBENSKY, Jr. et al.	
		Filing Date February 6, 2004	Group Art Unit 1645
		Mailing Date January 6, 2005	

57.	Ikonomidis, G. et al. (1994). "Delivery of a Viral Antigen to the Class I Pathway by <i>Listeria monocytogenes</i> : A Potential Vaccine Vector," <i>Abstracts of the 94th General Meeting of the American Society For Microbiology</i> (May 23-27, 1994) Las Vegas Convention Center: Las Vegas, NV pg. 159, Abstract No. E-90.
58.	Ikonomidis, G. et al. (December 1994). "Delivery of a Viral Antigen to the Class I Processing and Presentation Pathway by <i>Listeria monocytogenes</i> ," <i>J. Exp. Med.</i> 180:2209-2218.
59.	International Search Report mailed December 7, 2004, for PCT/US2004/003429 filed February 6, 2004, 11 pages.
60.	Jones, S. et al. (December 1994). "Characterization of <i>Listeria monocytogenes</i> Pathogenesis in a Strain Expressing Perfringolysin O in Place of Listeriolysin O," <i>Infection and Immunity</i> 62(12):5608-5613.
61.	Kim, J.J. et al. (April 2001). "Construction and Analysis of Photolyase Mutants of <i>Pseudomonas aeruginosa</i> and <i>Pseudomonas syringae</i> : Contribution of Photoreactivation, Nucleotide Excision Repair, and Mutagenic DNA Repair to Cell Survival and Mutability following Exposure to UV-B Radiation," <i>Applied and Environmental Microbiology</i> 67(4):1405-1411.
62.	Lecuit, M. et al. (June 1, 2001). "A Transgenic Model for Listeriosis: Role of Internalin in Crossing the Intestinal Barrier," <i>Science</i> 292:1722-1725.
63.	Lin, L. et al. (April 1997). "Photochemical Inactivation of Viruses and Bacteria in Platelet Concentrates by Use of a Novel Psoralen and Long-Wavelength Ultraviolet Light," <i>Transfusion</i> 37(4):423-435.
64.	Mandl, S. et al. (July 1998). "Poliovirus Vaccine Vectors Elicit Antigen-Specific Cytotoxic T Cells and Protect Mice Against Lethal Challenge with Malignant Melanoma Cells Expressing a Model Antigen," <i>Proc. Natl. Acad. Sci. USA</i> 95:8216-8221.
65.	Pan, Z-K. et al. (May 1995). "A Recombinant <i>Listeria monocytogenes</i> Vaccine Expressing a Model Tumour Antigen Protects Mice Against Lethal Tumour Cell Challenge and Causes Regression of Established Tumours," <i>Nature Medicine</i> 1(5):471-477.
66.	Pan, Z-K. et al. (November 1, 1995). "Regression of Established Tumors in Mice Mediated by the Oral Administration of a Recombinant <i>Listeria monocytogenes</i> Vaccine," <i>Cancer Research</i> 55:4776-4779.
67.	Parida, S.K. et al. (April 1998). "Internalin B is Essential for Adhesion and Mediates the Invasion of <i>Listeria monocytogenes</i> into Human Endothelial Cells," <i>Molecular Microbiology</i> 28(1):81-93.
68.	Peters, C. et al. (January 2003). "Tailoring Host Immune Responses to <i>Listeria</i> by Manipulation of Virulence Genes - The Interface Between Innate and Acquired Immunity," <i>FEMS Immunology and Medical Microbiology</i> 35:243-253.
69.	Sander, P. et al. (June 2001). " <i>Mycobacterium bovis</i> BCG <i>recA</i> Deletion Mutant Shows Increased Susceptibility to DNA-Damaging Agents but Wild-Type Survival in a Mouse Infection Model," <i>Infection and Immunity</i> 69(6):3562-3568.

EXAMINER:	DATE CONSIDERED: 1/17/01
EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.	

PTO/SB/08 (2-92)
pa- 901679

Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE



TFW

PATENT
Docket No. 282172002900

CERTIFICATE OF MAILING BY "FIRST CLASS MAIL"

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in a box addressed to: Mail Stop Amendment, Commissioner for Patents, PO Box 1450, Alexandria, VA 22313-1450, on July 21, 2004.

Sandy Yi

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the application of:

Thomas W. DUBENSKY, Jr. et al.

Serial No.: 10/773,792

Filing Date: February 6, 2004

For: LISTERIA ATTENUATED FOR ENTRY
INTO NON-PHAGOCYtic CELLS,
VACCINES COMPRISING THE
LISTERIA, AND METHODS OF USE
THEREOF

Examiner: Not Yet Assigned

Group Art Unit: 1616

INFORMATION DISCLOSURE
STATEMENT UNDER 37 C.F.R. § 1.97 & 1.98

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Dear Sir:

Pursuant to 37 C.F.R. § 1.97 and § 1.98, Applicants submit for consideration in the above-identified application the documents listed on the attached Form PTO-1449. Pursuant to the USPTO notice dated July 11, 2003, waiving the requirement under 37 C.F.R. § 1.98 (a)(2)(i) to provide copies of U.S. Patents and U.S. Published Applications, copies of those references are

not submitted. Copies of foreign documents and non-patent literature are submitted herewith.
The Examiner is requested to make these documents of record in the application.

This Information Disclosure Statement is submitted:

- ☐ With the application; accordingly, no fee or separate requirements are required.
- ☐ Before the mailing of a first Office Action after the filing of a Request for Continued Examination under § 1.114. However, if applicable, a certification under 37 C.F.R. § 1.97(e)(1) has been provided.
- ☒ Within three months of the application filing date or before mailing of a first Office Action on the merits; accordingly, no fee or separate requirements are required. However, if applicable, a certification under 37 C.F.R. § 1.97(e)(1) has been provided.
- ☐ After receipt of a first Office Action on the merits but before mailing of a final Office Action or Notice of Allowance.
 - ☐ A fee is required. A check in the amount of __ is enclosed.
 - ☐ A fee is required. Accordingly, a Fee Transmittal form (PTO/SB/17) is attached to this submission in duplicate.
 - ☐ A Certification under 37 C.F.R. § 1.97(e) is provided above; accordingly; no fee is believed to be due.
- ☐ After mailing of a final Office Action or Notice of Allowance, but before payment of the issue fee.
 - ☐ A Certification under 37 C.F.R. § 1.97(e) is provided above and a check in the amount of __ is enclosed.
 - ☐ A Certification under 37 C.F.R. § 1.97(e) is provided above and a Fee Transmittal form (PTO/SB/17 is attached to this submission in duplicate.)

Applicants would appreciate the Examiner initialing and returning the Form PTO-1449, indicating that the information has been considered and made of record herein.


The information contained in this Information Disclosure Statement under 37 C.F.R. § 1.97 and § 1.98 is not to be construed as a representation that: (i) a complete search has been made; (ii) additional information material to the examination of this application does

not exist; (iii) the information, protocols, results and the like reported by third parties are accurate or enabling; or (iv) the above information constitutes prior art to the subject invention.

In the unlikely event that the transmittal form is separated from this document and the Patent Office determines that an extension and/or other relief (such as payment of a fee under 37 C.F.R. §1.17(p)) is required, Applicants petition for any required relief including extensions of time and authorize the Commissioner to charge the cost of such petitions and/or other fees due in connection with the filing of this document to Deposit Account No. 03-1952 referencing 282172002900. However, the Commissioner is not authorized to charge the cost of the issue fee to the Deposit Account.

Dated: July 21, 2004

Respectfully submitted,

By: 
Alicia J. Hager
Registration No. 44,140

Morrison & Foerster LLP
755 Page Mill Road
Palo Alto, California 94304-1018
Telephone: (650) 813-4296
Facsimile: (650) 494-0792



PTO/SB/21 (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM (to be used for all correspondence after initial filing)		Application Number	10/773,792
		Filing Date	February 6, 2004
		First Named Inventor	Thomas W. DUBENSKY, Jr.
		Art Unit	1616
		Examiner Name	Not Yet Assigned
Total Number of Pages in This Submission	28 + 159 refs.	Attorney Docket Number	282172002900

ENCLOSURES (Check all that apply)

<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment/Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input checked="" type="checkbox"/> Information Disclosure Statement (3 pages) <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Response to Missing Parts/ Incomplete Application <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____	<input type="checkbox"/> After Allowance Communication to Group <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): 1. Form PTO-1449 + copy (24 pages) 2. 159 References 3. Return postcard
Remarks		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm or Individual name	MORRISON & FOERSTER LLP (Customer No. 25226) Alicia J. Hager - 44,140
Signature	
Date	July 21, 2004

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail, in a box addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

Dated: July 21, 2004

Signature:

(Sandy Yi)



Form PTO/SB/449

INFORMATION DISCLOSURE CITATION
IN AN APPLICATION

(Use several sheets if necessary)

Docket Number 282172002900

Application Number 10/773,792

Applicant

Thomas W. DUBENSKY, Jr. et al.

Filing Date February 6, 2004

Group Art Unit 1616

Mailing Date July 21, 2004

U.S. PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Name	Class	Subclass	Filing Date If Appropriate
	1.	02/28/2002	2002/0025323	Paterson et al.			
	2.	03/07/2002	2002/0028206	Paterson			
	3.	04/18/2002	2002/0045587	Goebel			
	4.	10/17/2002	2002/0150588	Allison et al.			
	5.	05/01/2003	2003/0082510	Wollowitz et al.			
	6.	06/19/2003	2003/0113704	Stassinopoulos et al.			
	7.	10/30/2003	2003/0202985	Paterson			
	8.	10/30/2003	2003/0203472	Portnoy et al.			
	9.	01/22/2004	2004/0013690	Portnoy et al.			
	10.	02/12/2004	2004/0029897	Cook et al.			
	11.	12/15/1992	5,171,568	Burke et al.			
	12.	01/19/1993	5,180,819	Cayre			
	13.	03/21/1995	5,399,719	Wollowitz et al.			
	14.	01/14/1997	5,593,823	Wollowitz et al.			
	15.	11/25/1997	5,691,132	Wollowitz et al.			
	16.	11/03/1998	5,830,702	Portnoy et al.			
	17.	12/01/1998	5,843,459	Wang et al.			
	18.	03/02/1999	5,877,159	Powell et al.			
	19.	12/21/1999	6,004,815	Portnoy et al.			
	20.	04/18/2000	6,051,237	Paterson			
	21.	07/25/2000	6,093,725	Cook et al.			
	22.	08/08/2000	6,099,848	Frankel et al.			
	23.	10/17/2000	6,133,460	Wollowitz et al.			
	24.	11/07/2000	6,143,490	Cook et al.			
	25.	11/07/2000	6,143,551	Goebel			
	26.	11/21/2000	6,150,170	Powell et al.			

EXAMINER:

DATE CONSIDERED:


EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

Form PTO-1449 INFORMATION DISCLOSURE CITATION IN AN APPLICATION <i>(Use several sheets if necessary)</i>	Docket Number 282172002900	Application Number 10/773,792
	Applicant Thomas W. DUBENSKY, Jr. et al.	
	Filing Date February 6, 2004	Group Art Unit 1616
	Mailing Date July 21, 2004	

27.	11/28/2000	6,153,430	Pastan et al.			
28.	08/07/2001	6,270,952	Cook et al.			
29.	09/11/2001	6,287,556	Portnoy et al.			
30.	09/24/2002	6,455,286	Wollowitz et al.			
31.	02/04/2003	6,514,987	Cook et al.			
32.	05/20/2003	6,565,852	Paterson			
33.	08/12/2003	6,605,286	Steidler et al.			

FOREIGN PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Country	Class	Subclass	Translation YES NO	
J	34.	06/01/1989	WO 89/04669	WIPO				
	35.	10/04/1990	WO 90/11089	WIPO				
	36.	11/29/1990	WO 90/14436	WIPO				
	37.	08/05/1993	WO 93/15212	WIPO	Abstract only		Abstract	
	38.	05/17/1996	WO 96/14087	WIPO				
	39.	01/22/1998	WO 98/02523	WIPO				
	40.	07/16/1998	WO 98/30545	WIPO				
	41.	07/23/1998	WO 98/31786	WIPO				
	42.	05/27/1999	WO 99/25376	WIPO				
	43.	06/03/1999	WO 99/26476	WIPO				
	44.	07/08/1999	WO 99/34007	WIPO				
	45.	09/23/1999	WO 99/47646	WIPO				
	46.	02/08/2001	WO 01/08701	WIPO				
	47.	04/12/2001	WO 01/24637	WIPO				
	48.	04/19/2001	WO 01/27295	WIPO	Abstract only		Abstract	
	49.	10/04/2001	WO 01/72329	WIPO				
	50.	06/27/2002	WO 02/50262	WIPO				

EXAMINER: 	DATE CONSIDERED: 11/17/04
---	---------------------------


EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

Form PTO-1449 INFORMATION DISCLOSURE CITATION IN AN APPLICATION <i>(Use several sheets if necessary)</i>	Docket Number 282172002900	Application Number 10/773,792
	Applicant Thomas W. DUBENSKY, Jr. et al.	
	Filing Date February 6, 2004	Group Art Unit 1616
	Mailing Date July 21, 2004	



51.	08/15/2002	WO 02/062298	WIPO				
52.	10/03/2002	WO 02/077249	WIPO				
53.	12/05/2002	WO 02/097044	WIPO				
54.	07/31/2003	WO 03/061379	WIPO				
55.	11/13/2003	WO 03/092600	WIPO				
56.	12/11/2003	WO 03/102168	WIPO				
57.	01/22/2004	WO 2004/006837	WIPO				

OTHER DOCUMENTS *(including author, title, Date, Pertinent Pages, Etc.)*

Examiner Initials	Ref. No.	Title
	58.	Aggarwal, A. et al. (October, 1990). "Oral <i>Salmonella</i> : Malaria Circumsporozoite Recombinants Induce Specific CD8 ⁺ Cytotoxic T Cells," <i>J. Exp. Med.</i> 172:1083-1090.
	59.	Angelakopoulos, H. et al. (July, 2002). "Safety and Shedding of an Attenuated Strain of <i>Listeria monocytogenes</i> with a Deletion of <i>actA/plcB</i> in Adult Volunteers: A Dose Escalation Study of Oral Inoculation," <i>Infection and Immunity</i> 70(7):3592-3601.
	60.	Anthoney, D.A. et al. (2001). "DNA: Still A Target Worth Aiming At?" <i>Am. J. Pharmacogenomics</i> 1(1):67-81.
	61.	Appelberg, R. et al. (February, 2000) "Mutants of <i>Listeria monocytogenes</i> Defective in In Vitro Invasion and Cell-to-Cell Spreading Still Invade and Proliferate in Hepatocytes of Neutropenic Mice," <i>Infection and Immunity</i> 68(2):912-914.
	62.	Aravind, L. et al. (1999). "Conserved Domains in DNA Repair Proteins and Evolution of Repair Systems," <i>Nucleic Acids Research</i> 27(5):1223-1242.
	63.	Argani, P. et al. (December, 2001). "Mesothelin Is Overexpressed in the Vast Majority of Ductal Adenocarcinomas of the Pancreas: Identification of a New Pancreatic Cancer Marker by Serial Analysis of Gene Expression (SAGE)," <i>Clin. Cancer Res.</i> 7:3862-3868.
	64.	Auerbuch, V. et al. (September, 2001). "Development of a Competitive Index Assay to Evaluate the Virulence of <i>Listeria monocytogenes actA</i> Mutants during Primary and Secondary Infection of Mice," <i>Infection and Immunity</i> 69(9):5953-5957.
	65.	Baer, R. et al. (July, 1984). "DNA Sequence and Expression of the B95-8 Epstein-Barr Virus Genome," <i>Nature</i> 310:207-211.
	66.	Bakardjiev, A. et al. (January, 2004). "Listeriosis in the Pregnant Guinea Pig: A Model of Vertical Transmission," <i>Infection and Immunity</i> 72(1):489-497.

EXAMINER: 	DATE CONSIDERED: 1/17/02
---	--------------------------

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

Form PTO-1449 INFORMATION DISCLOSURE CITATION IN AN APPLICATION (Use several sheets if necessary)		Docket Number 282172002900	Application Number 10/773,792
		Applicant Thomas W. DUBENSKY, Jr. et al.	
		Filing Date February 6, 2004	Group Art Unit 1616
		Mailing Date July 21, 2004	
<hr/>			
	67.	Ballard, J.D. et al. (1996). "Anthrax Toxin-Mediated Delivery of a Cytotoxic T-Cell Epitope <i>in vivo</i> ," <i>Proc. Natl. Acad. Sci. USA</i> 93:12531-12534.	
	68.	Bierne, H. et al. (September, 2002). "InlB, A Surface Protein of <i>Listeria monocytogenes</i> that Behaves as an Invasin and a Growth Factor," <i>Journal of Cell Science</i> 115:3357-3367.	
	69.	Bishop, D.K. et al. (September 15, 1987). "Adoptive Transfer of Immunity to <i>Listeria monocytogenes</i> : The Influence of In Vitro Stimulation on Lymphocyte Subset Requirements," <i>J. Immunol.</i> 139(6):2005-2009.	
	70.	Biswas, I. et al. (June, 1993). "High-Efficiency Gene Inactivation and Replacement System for Gram-Positive Bacteria," <i>J. Bacteriol.</i> 175(11):3628-3635.	
	71.	Bouwer, H.G.A. et al. (May 6, 2003). "Recombinant <i>L. monocytogenes</i> as a Vaccine For Stimulation of Anti-Tumor Responses," Poster, presented at <i>The American Association of Immunologists 90th Anniversary Meeting</i> , Denver, CO (May 6 -10, 2003). one page.	
	72.	Boyaka, P.N. et al. (1999). "IL-12 Is an Effective Adjuvant for Induction of Mucosal Immunity," <i>The Journal of Immunology</i> 162:122-128.	
	73.	Boyaka, P.N. et al. (June, 2003). "Effective Mucosal Immunity to Anthrax: Neutralizing Antibodies and Th Cell Responses Following Nasal Immunization with Protective Antigen," <i>The Journal of Immunology</i> 170:5636-5643.	
	74.	Brinkmann, U. et al. (April 1, 1999). "Novel Genes in the PAGE and GAGE Family of Tumor Antigens Found by Homology Walking in the dbEST Database," <i>Cancer Research</i> 59:1445-1448.	
	75.	Brockstedt, D. et al. (February 19, 2003). "Recombinant Attenuated <i>Listeria Monocytogenes</i> Elicits Striking Antigen-Specific CD8+ T-Cell Responses that Correlate with Prolonged Survival in a Murine Transplant Model of Melanoma," presented at <i>Keystone Symposia Meeting</i> , Keystone, CO (February 17 - 23, 2003) one page.	
	76.	Brockstedt, D. et al. (March 10, 2003). "Recombinant Attenuated <i>Listeria monocytogenes</i> Elicits Robust Cellular Immune Response to Tumor-Associated Antigen in <i>Listeria</i> Immune Mice," Abstract #851, posted online at <i>Days of Molecular Medicine Symposium</i> website, one page.	
	77.	Brockstedt, D. et al. (October 3, 2003). "Novel Strategies to Develop <i>Listeria monocytogenes</i> Vaccine Strains for Cancer Immunotherapy Applications," Poster, presented at <i>Cancer Vaccines 2003</i> , (October 1 -3, 2003), one page.	
	78.	Brook, I. et al. (2001). "Susceptibility of Irradiated Mice to <i>Bacillus anthracis</i> Sterne by the Intratracheal Route of Infection," <i>J. Med. Microbiol.</i> 50:702-711.	
	79.	Brossier, F. et al. (April, 2000). "Role of Toxin Functional Domains in Anthrax Pathogenesis," <i>Infection and Immunity</i> 68(4):1781-1786.	
	80.	Brossier, F. et al. (October, 2000). "Protective Antigen-Mediated Antibody Response Against a Heterologous Protein Produced In Vivo by <i>Bacillus anthracis</i> ," <i>Infection and Immunity</i> 68(10):5731-5734.	
EXAMINER: 		DATE CONSIDERED: 11/7/02	
EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.			
PTO/SB/ 08 (2-92) pa- 872134		Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE	

Form PTO-1449 INFORMATION DISCLOSURE CITATION IN AN APPLICATION <i>(Use several sheets if necessary)</i>		Docket Number 282172002900 Application Number 10/773,792 <hr/> Applicant <div style="text-align: center;">Thomas W. DUBENSKY, Jr. et al.</div> <hr/> Filing Date February 6, 2004 Group Art Unit 1616 <hr/> Mailing Date July 21, 2004	
<div style="font-size: 2em; margin-top: 20px;">9</div>	81.	Brown, E.R. et al. (1955). "Specific Identification of <i>Bacillus Anthracis</i> by Means of a Variant Bacteriophage," <i>J. Infect. Dis.</i> 96:34-39.	
	82.	Camilli, A. et al. (1993). "Dual Roles of <i>plcA</i> in <i>Listeria monocytogenes</i> Pathogenesis," <i>Molecular Microbiology</i> 8(1):143-157.	
	83.	Campbell, P.A. (1994). "Macrophage- <i>Listeria</i> Interactions" Chapter 19 <i>In Macrophage Pathogen Interactions</i> Marcel Dekker, Inc. 60:313-328.	
	84.	Carles-Kinch, K. et al. (May 15, 2002). "Antibody Targeting of the EphA2 Tyrosine Kinase Inhibits Malignant Cell Behavior," <i>Cancer Research</i> 62:2840-2847.	
	85.	Chee, M.S. et al. (1990). "Analysis of the Protein-Coding Content of the Sequence of Human Cytomegalovirus Strain AD169" <i>In Cytomegaloviruses</i> McDougall, J.K. ed. Springer Verlag 154: 125-169.	
	86.	Cheo, D.L. et al. (September, 1993). "Elucidation of Regulatory Elements That Control Damage Induction and Competence Induction of the <i>Bacillus subtilis</i> SOS System," <i>J. Bacteriol.</i> 175(18):5907-5915.	
	87.	Cossart, P. et al. (1998). "Interactions of <i>Listeria monocytogenes</i> With Mammalian Cells During Entry and Actin-Based Movement: Bacterial Factors, Cellular Ligands and Signaling," <i>The EMBO Journal</i> 17(14):3797-3806.	
	88.	Cossart, P. et al. (2001). "The Use of Host Cell Machinery in the Pathogenesis of <i>Listeria monocytogenes</i> ," <i>Current Opinion in Immunology</i> 13:96-103.	
	89.	Cossart, P. et al. (January, 2003). "Invasion of Mammalian Cells by <i>Listeria monocytogenes</i> : Functional Mimicry to Subvert Cellular Functions," <i>TRENDS in Cell Biology</i> 13(1):23-31.	
	90.	Da Ros, T. et al. (2001). "DNA-Photocleavage Agents," <i>Current Pharmaceutical Design</i> 7:1781-1821.	
	91.	Davison, A.J. et al. (1986). "The Complete DNA Sequence of Varicella-Zoster Virus," <i>J. Gen. Virol.</i> 67:1759-1816.	
	92.	Decatur, A.L. et al. (November 3, 2000). "A PEST-Like Sequence in Listeriolysin O Essential for <i>Listeria monocytogenes</i> Pathogenicity," <i>Science</i> 290:992-995.	
	93.	Domann, E. et al. (January, 1997). "Identification and Characterization of a Novel PrfA-Regulated Gene in <i>Listeria monocytogenes</i> Whose Product, IrpA, Is Highly Homologous to Internalin Proteins, Which Contain Leucine-Rich Repeats," <i>Infection and Immunity</i> 65(1):101-109.	
	94.	Dramsi, S. et al. (1995). "Entry of <i>Listeria monocytogenes</i> Into Hepatocytes Requires Expression of InlB, a Surface Protein of the Internalin Multigene Family," <i>Molecular Microbiology</i> 16(2):251-261.	
<div style="font-size: 2em; margin-top: 20px;">4</div>	95.	Dramsi, S. et al. (May, 1997). "Identification of Four New Members of the Internalin Multigene Family of <i>Listeria monocytogenes</i> EGD," <i>Infection and Immunity</i> 65(5):1615-1625.	
EXAMINER:		DATE CONSIDERED: 11/7/07	
EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.			
PTO/SB/ 08 (2-92) pa- 872134		Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE	

Form PTO-1449 INFORMATION DISCLOSURE CITATION IN AN APPLICATION (Use several sheets if necessary)		Docket Number 282172002900	Application Number 10/773,792
		Applicant Thomas W. DUBENSKY, Jr. et al.	
		Filing Date February 6, 2004	Group Art Unit 1616
		Mailing Date July 21, 2004	

96.	Dubensky, T. (February 22, 2003). "Cancer Vaccines Derived from Selected Attenuated Strains of <i>Listeria Monocytogenes</i> ," <i>presented at Keystone Symposia Meeting</i> , Keystone, CO (February 17 - 23, 2003) 22 pages.
97.	Dubensky, T. (March 14, 2003). "Cancer Vaccines Derived From Selected Attenuated Strains of <i>Listeria Monocytogenes</i> ," <i>presented at Days of Molecular Medicine - Immunotherapy</i> , 24 pages.
98.	Dubensky, T. (December 4, 2003). "Listeria-Based Therapeutic Vaccines for Infectious Disease and Cancer: Vaccines Disguised as an Invading Pathogen," <i>presented at Johns Hopkins University</i> , 57 pages.
99.	Esin, S. et al. (1996). "Proliferation of Distinct Human T Cell Subsets in Response to Live, Killed or Soluble Extracts of <i>Mycobacterium tuberculosis</i> and <i>Myco. avium</i> ," <i>Clin. Exp. Immunol.</i> 104:419-425.
100.	Fong, L. et al. (July 17, 2001). "Altered Peptide Ligand Vaccination with Flt3 Ligand Expanded Dendritic Cells for Tumor Immunotherapy," <i>Proc. Natl. Acad. Sci. USA</i> 98(15):8809-8814.
101.	Foon, K.A. et al. (November, 1995). "Immune Responses in Patients with T-Cell Lymphoma Treated with an Anti-Idiotypic Antibody Mimicking a Highly Restricted T-Cell Antigen," <i>Clin. Cancer Res.</i> 1:1285-1294.
102.	Gaillard, J.-L. et al. (June 28, 1991). "Entry of <i>L. Monocytogenes</i> into Cells Is Mediated by Internalin, a Repeat Protein Reminiscent of Surface Antigens From Gram-Positive Cocci," <i>Cell</i> 65:1127-1141.
103.	Gedde, M.M. et al. (February, 2000). "Role of Listeriolysin O in Cell-To-Cell Spread of <i>Listeria monocytogenes</i> ," <i>Infection and Immunity</i> 68(2):999-1003.
104.	Gentshev, I. et al. (February, 2002). "Delivery of Protein Antigens and DNA by Attenuated Intracellular Bacteria," <i>Int. J. Med. Microbiol.</i> 291:577-582.
105.	Giedlin, M. et al. (March 9, 2004). "The Living Dead: Vaccines Against Microbial Pathogens Based on Psoralen-Killed Metabolically Active DNA Repair Mutants," Poster, <i>presented at American Society for Microbiology Biodefense Research Meeting</i> (March 7-10, 2004) Baltimore, MD, one page.
106.	Glaser, P. et al. (October 26, 2001). "Comparative Genomics of <i>Listeria</i> Species," <i>Science</i> 294:849-852.
107.	Glomski, I.J. et al. (March 18, 2002). "The <i>Listeria monocytogenes</i> Hemolysin Has an Acidic pH Optimum to Compartmentalize Activity and Prevent Damage to Infected Host Cells," <i>Journal of Cell Biology</i> 156(6):1029-1038.
108.	Green, B.D. et al. (August, 1985). "Demonstration of a Capsule Plasmid in <i>Bacillus anthracis</i> ," <i>Infection and Immunity</i> 49(2):291-297.
109.	Gregory, S.H. et al. (October, 1996). "Expression of the <i>inlAB</i> Operon by <i>Listeria monocytogenes</i> Is Not Required for Entry into Hepatic Cells In Vivo," <i>Infection and Immunity</i> 64(10):3983-3986.


EXAMINER:	DATE CONSIDERED:
EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.	

PTO/SB/08 (2-92)
pa- 872134

Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Form PTO-1449 INFORMATION DISCLOSURE CITATION IN AN APPLICATION (Use several sheets if necessary)		Docket Number 282172002900	Application Number 10/773,792
		Applicant Thomas W. DUBENSKY, Jr. et al.	
		Filing Date February 6, 2004	Group Art Unit 1616
		Mailing Date July 21, 2004	

110.	Gregory, S.H. et al. (December, 1997). "Internalin B Promotes the Replication of <i>Listeria monocytogenes</i> in Mouse Hepatocytes," <i>Infection and Immunity</i> 65(12):5137-5141.
111.	Gunn, G.R. et al. (2001). "Two <i>Listeria monocytogenes</i> Vaccine Vectors That Express Different Molecular Forms of Human Papilloma Virus-16 (HPV-16) E7 Induce Qualitatively Different T Cell Immunity That Correlates with Their Ability to Induce Regression of Established Tumors Immortalized by HPV-16," <i>The Journal of Immunology</i> 167:6471-6479.
112.	Hammarström, S. (1999). "The Carcinoembryonic Antigen (CEA) Family: Structures, Suggested Functions and Expression in Normal and Malignant Tissues," <i>Seminars in Cancer Biology</i> 9:67-81.
113.	Harm, W. (1979). "Relative Effectiveness of the 300-320 NM Spectral Region of Sunlight For The Production of Primary Lethal Damage in <i>E. Coli</i> Cells," <i>Mutation Research</i> 60:263-270.
114.	Hei, D.J. et al. (March, 1999). "Elimination of Cytokine Production in Stored Platelet Concentrate Aliquots by Photochemical Treatment with Psoralen Plus Ultraviolet A Light," <i>Transfusion</i> 39:239-248.
115.	Hess, J. et al. (May, 1995). " <i>Listeria monocytogenes</i> p60 Supports Host Cell Invasion by and In Vivo Survival of Attenuated <i>Salmonella typhimurium</i> ," <i>Infection and Immunity</i> 63(5):2047-2053.
116.	Houghton, M. et al. (1991). "Molecular Biology of the Hepatitis C Viruses: Implications For Diagnosis, Development and Control of Viral Disease," <i>Hepatology</i> 14(2):381-388.
117.	Huang, E.H. et al. (June, 2002). "CEA-Based Vaccines," <i>Exper. Rev. Vaccines</i> 1(1):49-63.
118.	Ireton, K. et al. (June 11, 1999). "The <i>Listeria monocytogenes</i> Protein InlB Is an Agonist of Mammalian Phosphoinositide 3-Kinase," <i>The Journal of Biological Chemistry</i> 274(24):17025-17032.
119.	Jung, S. et al. (August, 2002). "In Vivo Depletion of CD11c ⁺ Dendritic Cells Abrogates Priming of CD8 ⁺ T Cells by Exogenous Cell-Associated Antigens," <i>Immunity</i> 17:211-220.
120.	Kawakami, Y. et al. (July, 1994). "Identification of a Human Melanoma Antigen Recognized by Tumor-Infiltrating Lymphocytes Associated with <i>in vivo</i> Tumor Rejection," <i>Proc. Natl. Acad. Sci. USA</i> 91:6458-6462.
121.	Kawashima, H. et al. (1984). "Functional Domains of <i>Escherichia coli</i> recA Protein Deduced From the Mutational Sites in the Gene," <i>Mol. Gen. Genet.</i> 193:288-292.
122.	Keogh, E. et al. (2001). "Identification of New Epitopes From Four Different Tumor-Associated Antigens: Recognition of Naturally Processed Epitopes Correlates with HLA-A*0201-Binding Affinity," <i>The Journal of Immunology</i> 167:787-796.
123.	Ko, M. et al. (July, 2002). "Group I Self-Splicing Intron in the <i>recA</i> Gene of <i>Bacillus anthracis</i> ," <i>J. Bacteriol.</i> 184(14):3917-3922.
124.	Kocks, C. et al. (February 7, 1992). " <i>L. monocytogenes</i> -Induced Actin Assembly Requires the <i>actA</i> Gene Product, a Surface Protein," <i>Cell</i> 68:521-531.

EXAMINER:	DATE CONSIDERED:
	11/7/04

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

PTO/SB/ 08 (2-92)
pa- 872134

Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Form PTO-1449 INFORMATION DISCLOSURE CITATION IN AN APPLICATION <i>(Use several sheets if necessary)</i>		<table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 50%;">Docket Number 282172002900</td> <td style="width: 50%;">Application Number 10/773,792</td> </tr> <tr> <td colspan="2">Applicant Thomas W. DUBENSKY, Jr. et al.</td> </tr> <tr> <td>Filing Date February 6, 2004</td> <td>Group Art Unit 1616</td> </tr> <tr> <td colspan="2">Mailing Date July 21, 2004</td> </tr> </table>		Docket Number 282172002900	Application Number 10/773,792	Applicant Thomas W. DUBENSKY, Jr. et al.		Filing Date February 6, 2004	Group Art Unit 1616	Mailing Date July 21, 2004	
Docket Number 282172002900	Application Number 10/773,792										
Applicant Thomas W. DUBENSKY, Jr. et al.											
Filing Date February 6, 2004	Group Art Unit 1616										
Mailing Date July 21, 2004											
125.		Kolb-Mäurer, A. et al. (June, 2000). " <i>Listeria monocytogenes</i> -Infected Human Dendritic Cells: Uptake and Host Cell Response," <i>Infection and Immunity</i> 68(6):3680-3688.									
126.		Lagè, C. et al. (November, 2003). "New Insights on How Nucleotide Excision Repair Could Remove DNA Adducts Induced by Chemotherapeutic Agents and Psoralens Plus UV-A (PUVA) in <i>Escherichia coli</i> cells," <i>Mutation Research</i> 544:143-157.									
127.		Lauer, P. et al. (August, 2002). "Construction, Characterization, and Use of Two <i>Listeria monocytogenes</i> Site-Specific Phage Integration Vectors," <i>Journal of Bacteriology</i> 184(15):4177-4186.									
128.		Lauvau, G. et al. (November 23, 2001). "Priming of Memory But Not Effector CD8 T Cells by a Killed Bacterial Vaccine," <i>Science</i> 294:1735-1739.									
129.		Lenz, L.L. et al. (October 14, 2003). "SecA2-Dependent Secretion of Autolytic Enzymes Promotes <i>Listeria monocytogenes</i> Pathogenesis," <i>Proc. Natl. Acad. Sci. USA</i> 100(21):12432-12437.									
130.		Leong, M. et al. (February 3, 2004). "Recombinant Attenuated <i>Listeria monocytogenes</i> Elicit Functional Immune Response Specific to a Heterologous Antigen in the Presence of <i>Listeria</i> -Specific Cellular and Humoral Immunity," <i>Gordon Research Conference on Immunochemistry & Immunobiology Conference</i> (February 1-6, 2004), Buellton, CA 20 pages.									
131.		Liau, L.M. et al. (April 15, 2002). "Tumor Immunity Within the Central Nervous System Stimulated by Recombinant <i>Listeria monocytogenes</i> Vaccination," <i>Cancer Research</i> 62:2287-2293.									
132.		Lillard, J.W. et al. (2001). "RANTES Potentiates Antigen-Specific Mucosal Immune Response," <i>The Journal of Immunology</i> 166:162-169.									
133.		Lim, S.H. et al. (March 1, 2001). "Sperm Protein 17 is a Novel Cancer-Testis Antigen in Multiple Myeloma," <i>Blood</i> 97(5):1508-1510.									
134.		Lin, L. (January/February, 1998). "Psoralen Photochemical Treatment of Platelets," <i>Science and Medicine</i> pp. 54-63.									
135.		Little, S.F. et al. (December, 1997). "Passive Protection by Polyclonal Antibodies Against <i>Bacillus anthracis</i> Infection in Guinea Pigs," <i>Infection and Immunity</i> 65(12):5171-5175.									
136.		Mansell, A. et al. (November 23, 2001). "Internalin B Activates Nuclear Factor- κ B via Ras, Phosphoinositide 3-Kinase, and Akt," <i>The Journal of Biological Chemistry</i> 276(47):43597-43603.									
137.		Marquis, H. et al. (June 16, 1997). "Proteolytic Pathways of Activation and Degradation of a Bacterial Phospholipase C During Intracellular Infection by <i>Listeria monocytogenes</i> ," <i>J. Cell Biol.</i> 137(6):1381-1392.									
138.		Mayordomo, J.I. et al. (December, 1995). "Bone Marrow-Derived Dendritic Cells Pulsed With Synthetic Tumour Peptides Elicit Protective and Therapeutic Antitumour Immunity," <i>Nat. Med.</i> 1(12):1297-1302.									
139.		McGeoch, D.J. et al. (1988). "The Complete DNA Sequence of the Long Unique Region in the Genome of Herpes Simplex Virus Type 1," <i>J. Gen Virol.</i> 69:1531-1574.									
EXAMINER:		DATE CONSIDERED:									
<p>EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.</p>											
PTO/SB/ 08 (2-92) pa- 872134		Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE									

Form PTO-1449		Docket Number 282172002900	Application Number 10/773,792
INFORMATION DISCLOSURE CITATION IN AN APPLICATION <i>(Use several sheets if necessary)</i>		Applicant Thomas W. DUBENSKY, Jr. et al.	
		Filing Date February 6, 2004	Group Art Unit 1616
		Mailing Date July 21, 2004	


140.	Mikesell, P. et al. (January, 1983). "Evidence for Plasmid-Mediated Toxin Production in <i>Bacillus anthracis</i> ," <i>Infection and Immunity</i> 39(1):371-376.
141.	Mitsuyama, M. et al. (May, 1990). "Difference in the Induction of Macrophage Interleukin-1 Production between Viable and Killed Cells of <i>Listeria monocytogenes</i> ," <i>Infection and Immunity</i> 58(5):1254-1260.
142.	Mock, M. et al. (2001). "Anthrax," <i>Ann. Rev. Microbiol.</i> 55:647-671.
143.	Molldrem J. et al. (October 1, 1996). "Targeted T-cell Therapy for Human Leukemia: Cytotoxic T Lymphocytes Specific for a Peptide Derived from Proteinase 3 Preferentially Lyse Human Myeloid Leukemia Cells," <i>Blood</i> 88(7):2450-2457.
144.	Molldrem, J.J. et al. (October 1, 1997). "Cytotoxic T Lymphocytes Specific for a Nonpolymorphic Proteinase 3 Peptide Preferentially Inhibit Chronic Myeloid Leukemia Colony-Forming Units," <i>Blood</i> 90(7):2529-2534.
145.	Molldrem, J.J. et al. (June 1, 1999). "A PR1-Human Leukocyte Antigen-A2 Tetramer Can Be Used to Isolate Low-Frequency Cytotoxic T Lymphocytes From Healthy Donors That Selectively Lyse Chronic Myelogenous Leukemia," <i>Cancer Research</i> 59:2675-2681.
146.	Molldrem, J.J. et al. (September, 2000). "Evidence That Specific T Lymphocytes May Participate in the Elimination of Chronic Myelogenous Leukemia," <i>Nature Medicine</i> 6(8):1018-1023.
147.	Molldrem, J.J. et al. (December, 2002). "The Basis of T-Cell-Mediated Immunity to Chronic Myelogenous Leukemia," <i>Oncogene</i> 21:8668-8673.
148.	Moors, M.A. et al. (January, 1999). "Expression of Listeriolysin O and ActA by Intracellular and Extracellular <i>Listeria monocytogenes</i> ," <i>Infection and Immunity</i> 67(1):131-139.
149.	Morgan, D.J. et al. (1998). "Activation of Low Avidity CTL Specific for a Self Epitope Results in Tumor Rejection But Not Autoimmunity," <i>J. Immunol.</i> 160:643-651.
150.	Morse, M.A. et al. (June, 1999). "A Phase I Study of Active Immunotherapy with Carcinoembryonic Antigen Peptide (CAP-1)-pulsed, Autologous Human Cultured Dendritic Cells in Patients with Metastatic Malignancies Expressing Carcinoembryonic Antigen," <i>Clin. Cancer Res.</i> 5:1331-1338.
151.	Muller-Berat, N. et al. (January, 1994). "The Phylogeny of Proteinase 3/Myeloblastin, The Autoantigen in Wegener's Granulomatosis, and Myeloperoxidase as Shown by Immunohistochemical Studies on Human Leukemic Cell Lines," <i>Clin. Immunol. Immunopath.</i> 70(1):51-59.
152.	Nicolaou, K.C. et al. (July, 1993). "Chemistry and Biology of Natural and Designed Enediynes," <i>Proc. Natl. Acad. Sci. USA</i> 90:5881-5888.
153.	Nishiyama, T. et al. (January, 2001). "Immunotherapy of Bladder Cancer Using Autologous Dendritic Cells Pulsed with Human Lymphocyte Antigen-A24-Specific MAGE-3 Peptide," <i>Clinical Cancer Research</i> 7:23-31.
154.	O'Riordan, M. et al. (October 17, 2003). " <i>Listeria</i> Intracellular Growth and Virulence Require Host-Derived Lipoic Acid," <i>Science</i> 302:462-464.

EXAMINER:	DATE CONSIDERED:
EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.	

PTO/SB/08 (2-92) Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
pa- 872134

Form PTO-1449 INFORMATION DISCLOSURE CITATION IN AN APPLICATION <i>(Use several sheets if necessary)</i>		Docket Number 282172002900	Application Number 10/773,792
		Applicant Thomas W. DUBENSKY, Jr. et al.	
		Filing Date February 6, 2004	Group Art Unit 1616
		Mailing Date July 21, 2004	
<hr/>			
155.	Pace, J.L. et al. (1998). "Inactivated Whole-Cell Bacterial Vaccines: Current Status and Novel Strategies," <i>Vaccine</i> 16(16):1563-1574.		
156.	Palucka, K. et al. (August, 1999). "Linking Innate and Adaptive Immunity," <i>Nature Medicine</i> 5(8):868-870.		
157.	Pan, Z-K. et al. (October 15, 1999). "Regression of Established B16F10 Melanoma with a Recombinant <i>Listeria monocytogenes</i> Vaccine," <i>Cancer Research</i> 59:5264-5269.		
158.	Portnoy, D.A. et al. (August 5, 2002). "The Cell Biology of <i>Listeria monocytogenes</i> Infection: The Intersection of Bacterial Pathogenesis and Cell-Mediated Immunity," <i>The Journal of Cell Biology</i> 158(3):409-414.		
159.	Price, B. M. et al. (July, 2001). "Protection Against Anthrax Lethal Toxin Challenge by Genetic Immunization with a Plasmid Encoding the Lethal Factor Protein," <i>Infection and Immunity</i> 69(7):4509-4515.		
160.	Raffelsbauer, D. et al. (1988). "The Gene Cluster <i>inlC2DE</i> of <i>Listeria monocytogenes</i> Contains Additional New Internalin Genes and Is Important for Virulence in Mice," <i>Mol. Gen. Genet.</i> 260:144-158.		
161.	Read, T.D. et al. (June 14, 2002). "Comparative Genome Sequencing For Discovery of Novel Polymorphisms in <i>Bacillus anthracis</i> ," <i>Science</i> 296:2028-2033.		
162.	Renkvist, N. et al. (2001). "A Listing of Human Tumor Antigens Recognized by T Cells," <i>Cancer Immunol. Immunother.</i> 50:3-15.		
163.	Rhie, G-E. et al. (September 16, 2003). "A Dually Active Anthrax Vaccine That Confers Protection Against Both Bacilli and Toxins," <i>Proc. Natl. Acad. Sci. USA</i> 100(19):10925-10930.		
164.	Rolph, M.S. et al. (2001). "CD40 Signaling Converts a Minimally Immunogenic Antigen into a Potent Vaccine Against the Intracellular Pathogen <i>Listeria monocytogenes</i> ," <i>The Journal of Immunology</i> 166:5115-5121.		
165.	Salazar, E. et al. (2000). "Agonist Peptide From a Cytotoxic T-Lymphocyte Epitope of Human Carcinoembryonic Antigen Stimulates Production of TC1-Type Cytokines and Increases Tyrosine Phosphorylation More Efficiently Than Cognate Peptide," <i>Int. J. Cancer</i> 85:829-838.		
166.	Sancar, A. et al. (1988). "DNA Repair Enzymes," <i>Ann. Rev. Biochem.</i> 57:29-67.		
167.	Schafer, R. et al. (July 1, 1992). "Induction of a Cellular Immune Response to a Foreign Antigen by a Recombinant <i>Listeria monocytogenes</i> Vaccine," <i>The Journal of Immunology</i> 149:53-59.		
168.	Sheehan, B. et al. (November, 1995). "Differential Activation of Virulence Gene Expression by PrfA, the <i>Listeria monocytogenes</i> Virulence Regulator," <i>Journal of Bacteriology</i> 177(22):6469-6476.		
169.	Shen, H. et al. (April, 1995). "Recombinant <i>Listeria monocytogenes</i> as a Live Vaccine Vehicle for the Induction of Protective Anti-Viral Cell-Mediated Immunity," <i>Proc. Natl. Acad. Sci. USA</i> 92:3987-3991.		
<hr/>			
EXAMINER:		DATE CONSIDERED: 11/17/07	
EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.			
PTO/SB/08 (2-92) pa- 872134		Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE	

Form PTO-1449 INFORMATION DISCLOSURE CITATION IN AN APPLICATION <i>(Use several sheets if necessary)</i>		<table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 50%;">Docket Number 282172002900</td> <td style="width: 50%;">Application Number 10/773,792</td> </tr> <tr> <td colspan="2">Applicant <div style="text-align: center;">Thomas W. DUBENSKY, Jr. et al.</div></td> </tr> <tr> <td>Filing Date February 6, 2004</td> <td>Group Art Unit 1616</td> </tr> <tr> <td colspan="2">Mailing Date July 21, 2004</td> </tr> </table>		Docket Number 282172002900	Application Number 10/773,792	Applicant <div style="text-align: center;">Thomas W. DUBENSKY, Jr. et al.</div>		Filing Date February 6, 2004	Group Art Unit 1616	Mailing Date July 21, 2004																					
Docket Number 282172002900	Application Number 10/773,792																														
Applicant <div style="text-align: center;">Thomas W. DUBENSKY, Jr. et al.</div>																															
Filing Date February 6, 2004	Group Art Unit 1616																														
Mailing Date July 21, 2004																															
<div style="border-left: 2px solid black; height: 100px; margin-left: 5px;"></div>	<div style="border-left: 2px solid black; height: 100px; margin-left: 5px;"></div>	<div style="border-left: 2px solid black; height: 100px; margin-left: 5px;"></div>	<table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 5%; text-align: center;">170.</td> <td>Shen, H. et al. (February 20, 1998). "Compartmentalization of Bacterial Antigens: Differential Effects on Priming of CD8 T Cells and Protective Immunity," <i>Cell</i> 92:535-545.</td> </tr> <tr> <td style="text-align: center;">171.</td> <td>Sinden, R.R. et al. (November, 1978). "Repair of Cross-Linked DNA and Survival of <i>Escherichia coli</i> Treated with Psoralen and Light: Effects of Mutations Influencing Genetic Recombination and DNA Metabolism," <i>Journal of Bacteriology</i> 136(2):538-547.</td> </tr> <tr> <td style="text-align: center;">172.</td> <td>Skoble, J. et al. (August 7, 2000). "Three Regions Within ActA Promote Arp2/3 Complex-Mediated Actin Nucleation and <i>Listeria monocytogenes</i> Motility," <i>The Journal of Cell Biology</i> 150(3):527-538.</td> </tr> <tr> <td style="text-align: center;">173.</td> <td>Slansky, J.E. et al. (October, 2000). "Enhanced Antigen-Specific Antitumor Immunity with Altered Peptide Ligands that Stabilize the MHC-Peptide-TCR Complex," <i>Immunity</i> 13:529-538.</td> </tr> <tr> <td style="text-align: center;">174.</td> <td>Song, F. et al. (1996). "Differential Effects of Viable and Killed Bacteria on IL-12 Expression of Macrophages," <i>The Journal of Immunology</i> 156:2979-2984.</td> </tr> <tr> <td style="text-align: center;">175.</td> <td>Starnbach, M.N. et al. (August, 2003). "Anthrax Delivers a Lethal Blow to Host Immunity," <i>Nature Medicine</i> 9(8):996-997.</td> </tr> <tr> <td style="text-align: center;">176.</td> <td>Subklewe, M. et al. (August 15, 1999). "Induction of Epstein-Barr Virus-Specific Cytotoxic T-Lymphocyte Responses Using Dendritic Cells Pulsed With EBNA-3A Peptides or UV-Inactivated, Recombinant EBNA-3A Vaccinia Virus," <i>Blood</i> 94(4):1372-1381.</td> </tr> <tr> <td style="text-align: center;">177.</td> <td>Sun, A. et al. (November, 1990). "Isolation of <i>Listeria monocytogenes</i> Small-Plaque Mutants Defective for Intracellular Growth and Cell-To-Cell Spread," <i>Infection & Immunity</i> 58(11):3770-3778.</td> </tr> <tr> <td style="text-align: center;">178.</td> <td>Tatsumi, T. et al. (August 1, 2003). "Disease Stage Variation in CD4+ and CD8+ T-Cell Reactivity to the Receptor Tyrosine Kinase EphA2 in Patients with Renal Cell Carcinoma," <i>Cancer Res.</i> 63(15):4481-4489.</td> </tr> <tr> <td style="text-align: center;">179.</td> <td>Tessman, J.W. et al. (1985). "Photochemistry of the Furan-Side 8-Methoxypsoralen-Thymidine Monoadduct Inside the DNA Helix. Conversion to Diadduct and to Pyrone-Side Monoadduct," <i>Biochemistry</i> 24:1669-1676.</td> </tr> <tr> <td style="text-align: center;">180.</td> <td>Thorne, C.B. et al. (1957). "An Agar-Diffusion Method for Titrating <i>Bacillus anthracis</i> Immunizing Antigen and its Application to a Study of Antigen Production," <i>J. Gen. Microbiol.</i> 17:505-516.</td> </tr> <tr> <td style="text-align: center;">181.</td> <td>Tilney, L. G. et al. (October, 1989). "Actin Filaments and the Growth, Movement, and Spread of the Intracellular Bacterial Parasite, <i>Listeria monocytogenes</i>," <i>The Journal of Cell Biology</i> 109:1597-1608.</td> </tr> <tr> <td style="text-align: center;">182.</td> <td>Tsang, K. Y. et al. (1995). "Generation of Human Cytotoxic T Cells Specific for Human Carcinoembryonic Antigen Epitopes From Patients Immunized With Recombinant Vaccinia-CEA Vaccine," <i>J. Natl. Cancer Inst.</i> 87(13):982-990.</td> </tr> <tr> <td style="text-align: center;">183.</td> <td>Tsung, K. et al. (January, 1996). "Gene Expression and Cytopathic Effect of Vaccinia Virus Inactivated by Psoralen and Long-Wave UV Light," <i>Journal of Virology</i> 70(1):165-171.</td> </tr> </table>	170.	Shen, H. et al. (February 20, 1998). "Compartmentalization of Bacterial Antigens: Differential Effects on Priming of CD8 T Cells and Protective Immunity," <i>Cell</i> 92:535-545.	171.	Sinden, R.R. et al. (November, 1978). "Repair of Cross-Linked DNA and Survival of <i>Escherichia coli</i> Treated with Psoralen and Light: Effects of Mutations Influencing Genetic Recombination and DNA Metabolism," <i>Journal of Bacteriology</i> 136(2):538-547.	172.	Skoble, J. et al. (August 7, 2000). "Three Regions Within ActA Promote Arp2/3 Complex-Mediated Actin Nucleation and <i>Listeria monocytogenes</i> Motility," <i>The Journal of Cell Biology</i> 150(3):527-538.	173.	Slansky, J.E. et al. (October, 2000). "Enhanced Antigen-Specific Antitumor Immunity with Altered Peptide Ligands that Stabilize the MHC-Peptide-TCR Complex," <i>Immunity</i> 13:529-538.	174.	Song, F. et al. (1996). "Differential Effects of Viable and Killed Bacteria on IL-12 Expression of Macrophages," <i>The Journal of Immunology</i> 156:2979-2984.	175.	Starnbach, M.N. et al. (August, 2003). "Anthrax Delivers a Lethal Blow to Host Immunity," <i>Nature Medicine</i> 9(8):996-997.	176.	Subklewe, M. et al. (August 15, 1999). "Induction of Epstein-Barr Virus-Specific Cytotoxic T-Lymphocyte Responses Using Dendritic Cells Pulsed With EBNA-3A Peptides or UV-Inactivated, Recombinant EBNA-3A Vaccinia Virus," <i>Blood</i> 94(4):1372-1381.	177.	Sun, A. et al. (November, 1990). "Isolation of <i>Listeria monocytogenes</i> Small-Plaque Mutants Defective for Intracellular Growth and Cell-To-Cell Spread," <i>Infection & Immunity</i> 58(11):3770-3778.	178.	Tatsumi, T. et al. (August 1, 2003). "Disease Stage Variation in CD4+ and CD8+ T-Cell Reactivity to the Receptor Tyrosine Kinase EphA2 in Patients with Renal Cell Carcinoma," <i>Cancer Res.</i> 63(15):4481-4489.	179.	Tessman, J.W. et al. (1985). "Photochemistry of the Furan-Side 8-Methoxypsoralen-Thymidine Monoadduct Inside the DNA Helix. Conversion to Diadduct and to Pyrone-Side Monoadduct," <i>Biochemistry</i> 24:1669-1676.	180.	Thorne, C.B. et al. (1957). "An Agar-Diffusion Method for Titrating <i>Bacillus anthracis</i> Immunizing Antigen and its Application to a Study of Antigen Production," <i>J. Gen. Microbiol.</i> 17:505-516.	181.	Tilney, L. G. et al. (October, 1989). "Actin Filaments and the Growth, Movement, and Spread of the Intracellular Bacterial Parasite, <i>Listeria monocytogenes</i> ," <i>The Journal of Cell Biology</i> 109:1597-1608.	182.	Tsang, K. Y. et al. (1995). "Generation of Human Cytotoxic T Cells Specific for Human Carcinoembryonic Antigen Epitopes From Patients Immunized With Recombinant Vaccinia-CEA Vaccine," <i>J. Natl. Cancer Inst.</i> 87(13):982-990.	183.	Tsung, K. et al. (January, 1996). "Gene Expression and Cytopathic Effect of Vaccinia Virus Inactivated by Psoralen and Long-Wave UV Light," <i>Journal of Virology</i> 70(1):165-171.
170.	Shen, H. et al. (February 20, 1998). "Compartmentalization of Bacterial Antigens: Differential Effects on Priming of CD8 T Cells and Protective Immunity," <i>Cell</i> 92:535-545.																														
171.	Sinden, R.R. et al. (November, 1978). "Repair of Cross-Linked DNA and Survival of <i>Escherichia coli</i> Treated with Psoralen and Light: Effects of Mutations Influencing Genetic Recombination and DNA Metabolism," <i>Journal of Bacteriology</i> 136(2):538-547.																														
172.	Skoble, J. et al. (August 7, 2000). "Three Regions Within ActA Promote Arp2/3 Complex-Mediated Actin Nucleation and <i>Listeria monocytogenes</i> Motility," <i>The Journal of Cell Biology</i> 150(3):527-538.																														
173.	Slansky, J.E. et al. (October, 2000). "Enhanced Antigen-Specific Antitumor Immunity with Altered Peptide Ligands that Stabilize the MHC-Peptide-TCR Complex," <i>Immunity</i> 13:529-538.																														
174.	Song, F. et al. (1996). "Differential Effects of Viable and Killed Bacteria on IL-12 Expression of Macrophages," <i>The Journal of Immunology</i> 156:2979-2984.																														
175.	Starnbach, M.N. et al. (August, 2003). "Anthrax Delivers a Lethal Blow to Host Immunity," <i>Nature Medicine</i> 9(8):996-997.																														
176.	Subklewe, M. et al. (August 15, 1999). "Induction of Epstein-Barr Virus-Specific Cytotoxic T-Lymphocyte Responses Using Dendritic Cells Pulsed With EBNA-3A Peptides or UV-Inactivated, Recombinant EBNA-3A Vaccinia Virus," <i>Blood</i> 94(4):1372-1381.																														
177.	Sun, A. et al. (November, 1990). "Isolation of <i>Listeria monocytogenes</i> Small-Plaque Mutants Defective for Intracellular Growth and Cell-To-Cell Spread," <i>Infection & Immunity</i> 58(11):3770-3778.																														
178.	Tatsumi, T. et al. (August 1, 2003). "Disease Stage Variation in CD4+ and CD8+ T-Cell Reactivity to the Receptor Tyrosine Kinase EphA2 in Patients with Renal Cell Carcinoma," <i>Cancer Res.</i> 63(15):4481-4489.																														
179.	Tessman, J.W. et al. (1985). "Photochemistry of the Furan-Side 8-Methoxypsoralen-Thymidine Monoadduct Inside the DNA Helix. Conversion to Diadduct and to Pyrone-Side Monoadduct," <i>Biochemistry</i> 24:1669-1676.																														
180.	Thorne, C.B. et al. (1957). "An Agar-Diffusion Method for Titrating <i>Bacillus anthracis</i> Immunizing Antigen and its Application to a Study of Antigen Production," <i>J. Gen. Microbiol.</i> 17:505-516.																														
181.	Tilney, L. G. et al. (October, 1989). "Actin Filaments and the Growth, Movement, and Spread of the Intracellular Bacterial Parasite, <i>Listeria monocytogenes</i> ," <i>The Journal of Cell Biology</i> 109:1597-1608.																														
182.	Tsang, K. Y. et al. (1995). "Generation of Human Cytotoxic T Cells Specific for Human Carcinoembryonic Antigen Epitopes From Patients Immunized With Recombinant Vaccinia-CEA Vaccine," <i>J. Natl. Cancer Inst.</i> 87(13):982-990.																														
183.	Tsung, K. et al. (January, 1996). "Gene Expression and Cytopathic Effect of Vaccinia Virus Inactivated by Psoralen and Long-Wave UV Light," <i>Journal of Virology</i> 70(1):165-171.																														
EXAMINER:		DATE CONSIDERED: 11/7/02																													
EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.																															
PTO/SB/ 08 (2-92) pa- 872134		Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE																													

Form PTO-1449		Docket Number 282172002900	Application Number 10/773,792
INFORMATION DISCLOSURE CITATION IN AN APPLICATION (Use several sheets if necessary)		Applicant Thomas W. DUBENSKY, Jr. et al.	
		Filing Date February 6, 2004	Group Art Unit 1616
		Mailing Date July 21, 2004	
9	184.	Uchida, I. et al. (1997). "Cross-Talk to the Genes for <i>Bacillus Anthracis</i> Capsule Synthesis by <i>atxA</i> , The Gene Encoding the <i>Trans</i> -Activator of Anthrax Toxin Synthesis," <i>Mol. Microbiol.</i> 23(6):1229-1240.	
	185.	Vazquez-Boland, J.A. et al. (July, 2001). " <i>Listeria</i> Pathogenesis and Molecular Virulence Determinants," <i>Chemical Microbiology Reviews</i> 14(3):584-640.	
	186.	Wemmer, D. (March, 1998). "Reading DNA," <i>Nature Structural Biology</i> 5(3):169-171.	
	187.	Wolfgang, C.D. et al. (August 15, 2000). "TARP: A Nuclear Protein Expressed in Prostate and Breast Cancer Cells Derived from an Alternate Reading Frame of the T Cell Receptor γ Chain Locus," <i>Proc. Natl. Acad. Sci. USA</i> 97(17):9437-9442.	
	188.	Wurtz, N.R. et al. (February 14, 2000). "Sequence Specific Alkylation of DNA by Hairpin Pyrrole-Imidazole Polyamide Conjugates," <i>Chemistry & Biology</i> 7:153-161.	
	189.	Xiong, H. et al. (1998). "Administration of Killed Bacteria Together with Listeriolysin O Induces Protective Immunity Against <i>Listeria monocytogenes</i> in Mice," <i>Immunology</i> 94:14-21.	
	190.	Zantek, N.D. et al. (September, 1999). "E-Cadherin Regulates the Function of the EphA2 Receptor Tyrosine Kinase," <i>Cell Growth Differ.</i> 10:629-638.	
	191.	Zaremba, S. et al. (October 15, 1997). "Identification of an Enhancer Agonist Cytotoxic T Lymphocyte Peptide From Human Carcinoembryonic Antigen," <i>Cancer Res.</i> 57:4570-4577.	
	192.	Zhou, Y. et al. (July, 2002). "Current Methods for Loading Dendritic Cells With Tumor Antigen for the Induction of Antitumor Immunity," <i>The Journal of Immunology</i> 25(4):289-303.	
EXAMINER:  DATE CONSIDERED: 11/7/09			
EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.			
PTO/SB/ 08 (2-92)		Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE	
pa- 872134			